EP1015006A2 - Cocoa extract compounds and methods for making and using the same - Google Patents
Cocoa extract compounds and methods for making and using the sameInfo
- Publication number
- EP1015006A2 EP1015006A2 EP97929671A EP97929671A EP1015006A2 EP 1015006 A2 EP1015006 A2 EP 1015006A2 EP 97929671 A EP97929671 A EP 97929671A EP 97929671 A EP97929671 A EP 97929671A EP 1015006 A2 EP1015006 A2 EP 1015006A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- sugar
- formula
- composition
- monomeric unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 327
- 238000000034 method Methods 0.000 title claims abstract description 206
- 229940119429 cocoa extract Drugs 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 claims abstract description 253
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims abstract description 238
- 229920002414 procyanidin Polymers 0.000 claims abstract description 238
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 229
- 239000000178 monomer Substances 0.000 claims abstract description 183
- 235000000346 sugar Nutrition 0.000 claims abstract description 135
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 115
- 239000001257 hydrogen Substances 0.000 claims abstract description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 86
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 64
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229920000642 polymer Polymers 0.000 claims abstract description 50
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 47
- 230000003647 oxidation Effects 0.000 claims abstract description 46
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 244000299461 Theobroma cacao Species 0.000 claims description 264
- 210000004027 cell Anatomy 0.000 claims description 164
- 230000000694 effects Effects 0.000 claims description 120
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 54
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 53
- 239000008103 glucose Substances 0.000 claims description 53
- 238000011282 treatment Methods 0.000 claims description 51
- 201000011510 cancer Diseases 0.000 claims description 45
- 239000000539 dimer Substances 0.000 claims description 39
- 239000013638 trimer Substances 0.000 claims description 38
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 37
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 37
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 36
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 36
- 235000019219 chocolate Nutrition 0.000 claims description 35
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 239000003963 antioxidant agent Substances 0.000 claims description 34
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 32
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 32
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 32
- 238000001727 in vivo Methods 0.000 claims description 32
- 239000002246 antineoplastic agent Substances 0.000 claims description 30
- 230000003078 antioxidant effect Effects 0.000 claims description 30
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- 102000003820 Lipoxygenases Human genes 0.000 claims description 28
- 108090000128 Lipoxygenases Proteins 0.000 claims description 28
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 27
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 27
- 239000003937 drug carrier Substances 0.000 claims description 27
- 210000002540 macrophage Anatomy 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 25
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 23
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 23
- 230000000845 anti-microbial effect Effects 0.000 claims description 23
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 22
- 201000001320 Atherosclerosis Diseases 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 20
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000012010 growth Effects 0.000 claims description 18
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 18
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 17
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 16
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 16
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 16
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 16
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 229930182830 galactose Natural products 0.000 claims description 16
- 150000007513 acids Chemical class 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 15
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 13
- 241000219161 Theobroma Species 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 12
- 208000037803 restenosis Diseases 0.000 claims description 12
- 241001556407 Herrania Species 0.000 claims description 11
- 229940034982 antineoplastic agent Drugs 0.000 claims description 11
- 210000001616 monocyte Anatomy 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 10
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 10
- 208000000389 T-cell leukemia Diseases 0.000 claims description 9
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 6
- 101710183280 Topoisomerase Proteins 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 claims description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000004792 oxidative damage Effects 0.000 claims description 4
- 238000003196 serial analysis of gene expression Methods 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 238000003633 gene expression assay Methods 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000002966 oligonucleotide array Methods 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 24
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 208000004729 Feline Leukemia Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000003610 anti-gingivitis Effects 0.000 claims 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 claims 1
- 229960001671 azapropazone Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 87
- 244000240602 cacao Species 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 192
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 171
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 129
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 98
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 231100000673 dose–response relationship Toxicity 0.000 description 44
- 238000000926 separation method Methods 0.000 description 40
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 238000004128 high performance liquid chromatography Methods 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 35
- 239000008280 blood Substances 0.000 description 35
- 238000003556 assay Methods 0.000 description 34
- 229910001868 water Inorganic materials 0.000 description 34
- 235000006708 antioxidants Nutrition 0.000 description 30
- 239000012071 phase Substances 0.000 description 30
- 230000001093 anti-cancer Effects 0.000 description 29
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 26
- 230000036772 blood pressure Effects 0.000 description 24
- 238000001228 spectrum Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 230000000259 anti-tumor effect Effects 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 19
- 235000012734 epicatechin Nutrition 0.000 description 19
- 235000013305 food Nutrition 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 238000005100 correlation spectroscopy Methods 0.000 description 18
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 108020003631 Kinetoplast DNA Proteins 0.000 description 15
- 238000004305 normal phase HPLC Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 14
- 235000005487 catechin Nutrition 0.000 description 14
- 229950001002 cianidanol Drugs 0.000 description 14
- 210000000540 fraction c Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 150000003254 radicals Chemical group 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 102100020870 La-related protein 6 Human genes 0.000 description 13
- 108050008265 La-related protein 6 Proteins 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000011894 semi-preparative HPLC Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 11
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 10
- 229960001948 caffeine Drugs 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 238000001551 total correlation spectroscopy Methods 0.000 description 10
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 9
- 235000007355 (-)-epicatechin Nutrition 0.000 description 9
- 229930013783 (-)-epicatechin Natural products 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- -1 Example 37) Chemical compound 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000008789 oxidative DNA damage Effects 0.000 description 9
- 238000005191 phase separation Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229960004559 theobromine Drugs 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 8
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 8
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000000287 crude extract Substances 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000007079 thiolysis reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 7
- 230000004075 alteration Effects 0.000 description 7
- 229940076005 apoptosis modulator Drugs 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000024883 vasodilation Effects 0.000 description 7
- 229930013915 (+)-catechin Natural products 0.000 description 6
- 235000007219 (+)-catechin Nutrition 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 101800004538 Bradykinin Proteins 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 102000030523 Catechol oxidase Human genes 0.000 description 6
- 108010031396 Catechol oxidase Proteins 0.000 description 6
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 6
- 241000590002 Helicobacter pylori Species 0.000 description 6
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 6
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 6
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 6
- 229940009456 adriamycin Drugs 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 229940037467 helicobacter pylori Drugs 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000004244 micellar electrokinetic capillary chromatography Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000002532 enzyme inhibitor Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003918 fraction a Anatomy 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000003359 percent control normalization Methods 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000001974 tryptic soy broth Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 4
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102100035882 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N deuterated acetone Substances [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 235000011846 forastero Nutrition 0.000 description 3
- 244000237494 forastero Species 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940044627 gamma-interferon Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 235000019220 whole milk chocolate Nutrition 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 2
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007816 calorimetric assay Methods 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 235000019221 dark chocolate Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000012361 double-strand break repair Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 229930182497 flavan-3-ol Natural products 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009920 food preservation Methods 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 2
- 229920000429 procyanidin dimer Polymers 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 230000001196 vasorelaxation Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BTQAFTBKHVLPEV-UHFFFAOYSA-N 3h-naphtho[2,3-e]indazole Chemical class C1=CC=CC2=CC3=C4C=NNC4=CC=C3C=C21 BTQAFTBKHVLPEV-UHFFFAOYSA-N 0.000 description 1
- CFBVWCHTNQHZLT-UHFFFAOYSA-N 4-methoxy-5-[3-(2-methoxy-4-nitro-5-sulfophenyl)-5-(phenylcarbamoyl)tetrazol-3-ium-2-yl]-2-nitrobenzenesulfonate Chemical compound COC1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C=C1N1[N+](C=2C(=CC(=C(C=2)S(O)(=O)=O)[N+]([O-])=O)OC)=NC(C(=O)NC=2C=CC=CC=2)=N1 CFBVWCHTNQHZLT-UHFFFAOYSA-N 0.000 description 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 244000283763 Acetobacter aceti Species 0.000 description 1
- 235000007847 Acetobacter aceti Nutrition 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000599985 Beijerinckia mobilis Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020005124 DNA Adducts Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 208000025939 DNA Repair-Deficiency disease Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 108010078339 DNA alkyltransferase Proteins 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 101150109636 Inos gene Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 229920002350 Procyanidin B2 Polymers 0.000 description 1
- GMISZFQPFDAPGI-HZZPXJBDSA-N Procyanidin B5 Natural products C1([C@@H]2[C@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=C3C[C@H]([C@H](OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-HZZPXJBDSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FQVWZTFVSA-N Procyanidin C1 Natural products O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]3[C@@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@H]1c1c(O)cc(O)c2c1O[C@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FQVWZTFVSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241001546666 Salmonella enterica subsp. enterica serovar Newport Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229960004701 amonafide Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002592 antimutagenic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000036778 atheroma formation Effects 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical compound [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- COKHRCLLFPZOEI-UHFFFAOYSA-N dercitin Natural products CN1C=CC2=C3C=CC=CC3=NC3=C2C1=C1SC=NC1=C3CCN(C)C COKHRCLLFPZOEI-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000003182 dose-response assay Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- DUKQZMHSXLRNSN-UHFFFAOYSA-N ethanol;nickel Chemical compound [Ni].CCO DUKQZMHSXLRNSN-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229930195472 nobotanin Natural products 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000007888 peripheral angioplasty Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical class O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 1
- GMISZFQPFDAPGI-UHFFFAOYSA-N proanthocyanidin B5 Natural products OC=1C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-UHFFFAOYSA-N 0.000 description 1
- GMISZFQPFDAPGI-CVJZBMGUSA-N procyanidin B5 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=C3C[C@H]([C@H](OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-CVJZBMGUSA-N 0.000 description 1
- MOJZMWJRUKIQGL-XILRTYJMSA-N procyanidin C1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C2=C3O[C@@H]([C@H](O)[C@H](C3=C(O)C=C2O)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 MOJZMWJRUKIQGL-XILRTYJMSA-N 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 239000012087 reference standard solution Substances 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010916 retrosynthetic analysis Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001004 secondary ion mass spectrometry Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 108010042747 stallimycin Proteins 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- ZHNNHZFCTWXJND-UHFFFAOYSA-L zinc;sulfate;dihydrate Chemical compound O.O.[Zn+2].[O-]S([O-])(=O)=O ZHNNHZFCTWXJND-UHFFFAOYSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Definitions
- This invention relates to cocoa extracts and compounds therefrom such as polyphenols preferably polyphenols enriched with procyanidins.
- This invention also relates to methods for preparing such extracts and compounds, as well as to uses for them; for instance, as antineoplastic agents, antioxidants, DNA topoisomerase II enzyme inhibitors, cyclo-oxygenase and/or lipoxygenase modulators, NO (Nitric Oxide) or NO-synthase modulators, as non-steroidal antiinflammatory agents, apoptosis modulators, platelet aggregation modulators, blood or in vivo glucose modulators, antimicrobials, and inhibitors of oxidative DNA damage.
- Polyphenols are an incredibly diverse group of compounds (Ferreira et al., 1992) which widely occur in a variety of plants, some of which enter into the food chain. In some cases they represent an important class of compounds for the human diet. Although some of the polyphenols are considered to be nonnutrative, interest in these compounds has arisen because of their possible beneficial effects on health.
- quercetin a flavonoid
- (+)-Catechin and (-)-epicatechin have been shown to inhibit Leukemia virus reverse transcriptase activity (Chu et al., 1992).
- Nobotanin an oligomeric hydrolyzable tannin
- Nobotanin has also been shown to possess anti-tumor activity (Okuda et al., 1992).
- Statistical reports have also shown that stomach cancer mortality is significantly lower in the tea producing districts of Japan.
- Epigallocatechin gallate has been reported to be the pharmacologically active material in green tea that inhibits mouse skin tumors (Okuda et al., 1992).
- Ellagic acid has also been shown to possess anticarcinogen activity in various animal tumor models (Bukharta et al., 1992).
- proanthocyanidin oligomers have been patented by the Kikkoman Corporation for use as antimutagens. Indeed, the area of phenolic compounds in foods and their modulation of tumor development in experimental animal models has been recently presented at the 202nd National Meeting of The American Chemical Society (Ho et al., 1992; Huang et al., 1992).
- cocoa extracts or compounds therefrom as antineoplastic agents, antioxidants, DNA topoisomerase II enzyme inhibitors, cyclo-oxygenase and/or lipoxygenase modulators, NO (Nitric Oxide) or NO- synthase modulators, as non-steroidal antiinflammatory agents, apoptosis modulators, platelet aggregation modulators, blood or in vivo glucose modulators, antimicrobials, or inhibitors of oxidative DNA damage.
- cocoa extracts e.g., compounds within cocoa
- the National Cancer Institute has screened various Theobroma and
- cocoa polyphenol extracts which contain procyanidins have significant utility as anti-cancer or antineoplastic agents.
- cocoa extracts containing procyanidins and compounds from cocoa extracts have utility as antineoplastic agents, antioxidants, DNA topoisomerase II enzyme inhibitors, cyclo-oxygenase and/or lipoxygenase modulators, NO
- NO-synthase modulators as non-steroidal antiinflammatory agents, apoptosis modulators, platelet aggregation modulators, blood or in vivo glucose modulators, antimicrobials, and inhibitors of oxidative DNA damage.
- n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and a plurality of additional monomeric units;
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-( ⁇ )-O-sugar, or 3- ( ⁇ )-O-sugar;
- a bond of an additional monomeric unit in position 4 has ⁇ or ⁇ stereochemistry
- the sugar is optionally substituted with a phenolic moiety at any position, for instance, via an ester bond,
- n is an integer from 2 to 18, e.g., 3 to 18;
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-(a)-O-sugar, or 3- ( ⁇ )-O-sugar;
- a bond at position 4 has a or ⁇
- the sugar is optionally substituted with a phenolic moiety at any position, for instance, via an ester bond,
- invention to provide a method for treating tumors or cancer.
- antineoplastic, antioxidant, antimicrobial, cyclo- oxygenase and/or lipoxygenase modulating or NO or NO- synthase modulating non-steroidal antiinflammatory modulating and/or blood or in vivo glucose-modulating composition is antineoplastic, antioxidant, antimicrobial, cyclo- oxygenase and/or lipoxygenase modulating or NO or NO- synthase modulating non-steroidal antiinflammatory modulating and/or blood or in vivo glucose-modulating composition.
- compositions and methods for apoptosis modulation It is still a further object of the invention to provide compositions and methods for apoptosis modulation. It is a further object of the invention to provide a method for making any of the aforementioned compositions.
- cocoa extract, and compounds therefrom have anti-tumor, anti- cancer or antineoplastic activity or, is an antioxidant composition or, inhibits DNA topoisomerase II enzyme activity or, is an antimicrobial or, is a cyclo-oxygenase and/or lipoxygenase modulator or, is a NO or NO-synthase modulator, is a non-steroidal antiinflammatory agent, apoptosis modulator, platelet aggregation modulator or, is a blood or in vivo glucose modulator, or is an antioxidant composition or, inhibits DNA topoisomerase II enzyme activity or, is an antimicrobial or, is a cyclo-oxygenase and/or lipoxygenase modulator or, is a NO or NO-synthase modulator, is a non-steroidal antiinflammatory agent, apoptosis modulator, platelet aggregation modulator or, is a blood or in vivo glucose modulator, or is an
- the present invention provides a substantially pure cocoa extract and compounds therefrom.
- the extract or compounds preferably comprises
- polyphenol (s) such as polyphenol (s) enriched with cocoa procyanidin (s), such as polyphenols of at least one cocoa procyanidin selected from (-) epicatechin, (+) catechin, procyanidin B-2, procyanidin oligomers 2 through 18, e.g., 3 through 18, such as 2 through 12 or 3 through 12, preferably 2 through 5 or 4 through 12, more preferably 3 through 12 , and most preferably 5 through 12, procyanidin B-5, procyanidin A-2 and procyanidin C-1.
- cocoa procyanidin such as polyphenols of at least one cocoa procyanidin selected from (-) epicatechin, (+) catechin, procyanidin B-2, procyanidin oligomers 2 through 18, e.g., 3 through 18, such as 2 through 12 or 3 through 12, preferably 2 through 5 or 4 through 12, more preferably 3 through 12 , and most preferably 5 through 12, procyanidin B-5, procyanidin A-2 and procyanidin C-1.
- the present invention also provides an anti- tumor, anti-cancer or antineoplastic or antioxidant or DNA topoisomerase II inhibitor, or antimicrobial, or cyclo-oxygenase and/or lipoxygenase modulator, or an NO or NO-synthase modulator, nonsteroidal antiinflammatory agent, apoptosis modulator, platelet aggregation
- oxidative DNA damage inhibitory composition comprising a substantially pure cocoa extract or compound therefrom or synthetic cocoa polyphenol (s) such as polyphenol (s) enriched with procyanidin(s) and a suitable carrier, e.g., a pharmaceutically, veterinary or food science acceptable carrier.
- the extract or compound therefrom preferably comprises cocoa procyanidin (s).
- the cocoa extract or compounds therefrom is preferably obtained by a process comprising reducing cocoa beans to powder, defatting the powder and, extracting and purifying active compound (s) from the powder.
- the present invention further comprehends a method for treating a patient in need of treatment with an anti-tumor, anti-cancer, or antineoplastic agent or an antioxidant, or a DNA topoisomerase II inhibitor, or antimicrobial, or cyclo-oxygenase and/or lipoxygenase modulator, or an NO or NO-synthase modulator, non- steroidal antiinflammatory agent, apoptosis modulator, platelet aggregation modulator, blood or in vivo glucose modulator or inhibitor of oxidative DNA damage,
- compositions comprising administering to the patient a composition comprising an effective quantity of a substantially pure cocoa extract or compound therefrom or synthetic cocoa polyphenol (s) or procyanidin(s) and a carrier, e.g., a pharmaceutically, veterinary or food science acceptable carrier.
- a carrier e.g., a pharmaceutically, veterinary or food science acceptable carrier.
- the cocoa extract or compound therefrom can be cocoa procyanidin (s); and, is preferably obtained by reducing cocoa beans to powder, defatting the powder and, extracting and purifying active compound (s) from the powder.
- the present invention provides a kit for treating a patient in need of treatment with an anti-tumor, anti-cancer, or antineoplastic agent or antioxidant or DNA topoisomerase II inhibitor, or
- antimicrobial, or cyclo-oxygenase and/or lipoxygenase modulator, or an NO or NO-synthase modulator, non- steroidal antiinflammatory agent, apoptosis modulator, platelet aggregation modulator inhibitor of oxidative DNA damage, or blood or in vivo glucose modulator comprising a substantially pure cocoa extract or compounds therefrom or synthetic cocoa polyphenol (s) or procyanidin (s) and a suitable carrier, e.g., a pharmaceutically, veterinary or food science acceptable carrier, for admixture with the extract or compound therefrom or synthetic polyphenol (s) or procyanidin(s).
- a suitable carrier e.g., a pharmaceutically, veterinary or food science acceptable carrier, for admixture with the extract or compound therefrom or synthetic polyphenol (s) or procyanidin(s).
- the present invention provides compounds as illustrated in Figs. 38A to 38P and 39A to 39AA; and linkages of 4 ⁇ 6 and 4 ⁇ 8 are presently preferred.
- the invention even further encompasses food preservation or preparation compositions comprising an inventive compound, and methods for preparing or
- DNA topoisomerase II inhibitor comprising an inventive compound and a suitable carrier or diluent, and methods for treating a patient in need of such treatment by administration of the composition.
- the invention also includes such embodiments wherein an inventive compound is used instead of or as the cocoa extracts.
- an inventive compound is used instead of or as the cocoa extracts.
- the invention comprehends kits, methods, and compositions analogous to those above-stated with regard to cocoa extracts and with an inventive compound.
- Fig. 1 shows a representative gel permeation chromatogram from the fractionation of crude cocoa procyanidins
- Fig. 2A shows a representative reverse-phhse
- Fig. 2B shows a representative normal phase HPLC separation of cocoa procyanidins extracted from unfermented cocoa
- Fig. 3 shows several representative procyanidin structures
- Figs. 4A-4E show representative HPLC chromatograms of five fractions employed in screening for anti-cancer or antineoplastic activity
- Figs. 5 and 6A-6D show the dose-response relationship between cocoa extracts and cancer cells ACHN (Fig. 5) and PC-3 (Figs. 6A-6D) (fractional survival vs. dose, ⁇ g/mL); M&M2 F4/92, M&MA+E U12P1, M&MB+E Y192P1, M&MC+E U12P2, M&MD+E U12P2;
- Figs. 7A to 7H show the typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, A+B, A+E, and A+D, and the PC-3 cell line
- Figs. 8A to 8H show the typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, A+B, B+E, and D+E and the KB Nasopharyngeal/HeLa cell line (fractional survival vs. dose, ⁇ g/mL);
- Figs. 9A to 9H show the typical dose response relationship between cocoa procyanidin fractions A, B, C, F E, B+D, A+E and D+E and the Hc ⁇ -116 cell line
- Figs. 10A to 10H show typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, B+D, C+D and A+E and the ACHN renal cell line (fractional survival vs. dose, ⁇ g/mL); MM-1 A 092A5, MM-1 B 092A5, MM-1 C 0192A7, MM-1 D 0192A7, M&M1 E 0192A7, MM- 1 B&D 0302A6, MM-1 C&D 0302A6, MM-1 A&E 0262A6;
- Figs. 11A to 11H show typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, A+E, B+E and C+E and the A-549 lung cell line (fractional survival vs. dose, ⁇ g/mL); MM-1 A 019258, MM- 1 B 09256, MM-1 C 019259, MM-1 D 019258, MM-1 E 019258, A/E 026254, MM-1 B&E 030255, MM-1 C&E N6255;
- Figs. 12A to 12H show typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, B+C, C+D and D+E and the SK-5 melanoma cell line (fractional survival vs. dose ⁇ g/mL); MM-1 A 0212S4, MM-1 B 0212S4, MM-1 C 0212S4, MM-1 D 0212S4, MM-1 E N32S1, MM-1 B&C N32S2, MM-1 C&D N32S3, MM-1 D&E N32S3;
- Figs. 13A to 13H show typical dose response relationships between cocoa procyanidin fractions A, B, C, D, E, B+C, C+E, and D+E and the M.CF-7 breast cell line (fractional survival vs. dose, ⁇ g/mL); MM-1 A N22M4, MM-1 B N22M4, MM-1 C N22M4, MM-1 D N22M3, MM-1 E 0302M2, MM-1 B/C 0302M4, MM-1 C&E N22M3, MM-1 D&E N22M3;
- Fig. 14 shows typical dose response
- fraction D and the CCRF-CEM T-cell leukemia cell line (cells/mL vs. days of growth; open circle is control, darkened circle is 125 ⁇ g fraction D, open inverted triangle is 250 ⁇ g fraction D, darkened inverted triangle is 500 ⁇ g fraction D);
- Fig. 15A shows a comparison of the XTT and Crystal Violet cytotoxicity assays against MCF-7 pl68 breast cancer cells treated with fraction D+E (open circle is XTT and darkened circle is Crystal Violet);
- Fig. 15B shows a typical dose response curve obtained from MDA MB231 breast cell line treated with varying levels of crude polyphenols obtained from UIT-1 cocoa genotype (absorbance (540nm) vs. Days; open circle is control, darkened circle is vehicle, open inverted triangle is 250 ⁇ g/mL, darkened inverted triangle is
- Fig. 15C shows a typical dose response curve obtained from PC-3 prostate cancer cell line treated with varying levels of crude polyphenols obtained from UIT-1 cocoa genotype (absorbance (540nm) vs. Days; open circle is control, darkened circle is vehicle, open inverted triangle is 250 ⁇ g/mL, darkened inverted triangle is 100 ⁇ g/mL and open square is 10 ⁇ g/mL);
- Fig. 15D shows a typical dose-response curve obtained from MCF-7 pl68 breast cancer cell line treated with varying levels of crude polyphenols obtained from UIT-1 cocoa genotype (absorbance (540nm) vs. Days; open circle is control, darkened circle is vehicle, open inverted triangle is 250 ⁇ g/mL, darkened inverted triangle is 100 ⁇ g/mL, open square is 10 ⁇ g/mL, darkened square is l ⁇ g/mL; absorbance of 2.0 is maximum of plate reader and may not be necessarily representative of cell number);
- Fig. 15E shows a typical dose response curve obtained from Hela cervical cancer cell line treated with varying levels of crude polyphenols obtained from UIT-1 cocoa genotype (absorbance (540nm) vs. Days; open circle is control, darkened circle is vehicle, open inverted triangle is 250 ⁇ g/mL, darkened inverted triangle is 100 ⁇ g/mL, open square is 10 ⁇ g/mL; absorbance of 2.0 is maximum of plate reader and may not be necessarily representative of cell number);
- Fig. 15F shows cytotoxic effects against Hela cervical cancer cell line treated with different cocoa polyphenol fractions (absorbance (540nm) vs. Days; open circle is 100 ⁇ g/mL fractions A-E, darkened circle is 100 ⁇ g/mL fractions A-C, open inverted triangle is
- Fig. 15G shows cytotoxic effects at 100ul/mL against SKBR-3 breast cancer cell line treated with different cocoa polyphenol fractions (absorbance (540nm) vs. Days; open circle is fractions A-E, darkened circle is fractions A-C, open inverted triangle is fractions D&E);
- Fig. 15H shows typical dose-response relationships between cocoa procyanidin fraction D+E on Hela cells (absorbance (540nm) vs. Days; open circle is control, darkened circle is 100 ⁇ g/mL, open inverted triangle is 75 ⁇ g/mL, darkened inverted triangle is
- Fig. 151 shows typical dose-response relationship between cocoa procyanidin fraction D+E on SKBR-3 cells (absorbance (540nm) vs. Days; open circle is control, darkened circle is 100 ⁇ g/mL, open inverted triangle is 75 ⁇ g/mL, darkened inverted triangle is
- Fig. 15J shows typical dose-response relationships between cocoa procyanidin fraction D+E on Hela cells using the Soft Agar Cloning assay (bar chart; number of colonies vs. control, 1, 10, 50, and 100 ⁇ g/mL);
- Fig. 15K shows the growth inhibition of Hela cells when treated with crude polyphenol extracts
- Fig. 15L shows the growth inhibition of Hela cells when treated with crude polyphenol extracts
- inverted triangle is day 2 fraction
- darkened inverted triangle is day 3 fraction
- open square is day 4 fraction
- darkened square is day 9 fraction
- Fig. 15M shows the effect of enzymatically oxidized cocoa procyanidins against Hela cells (dose response for polyphenol oxidase treated crude cocoa polyphenol; % control vs. concentration, ⁇ g/mL; darkened square is crude UIT-1 (with caffeine and theobromine), open circle crude UIT-1 (without caffeine and
- Fig. 15N shows a representative semi- preparative reverse phase HPLC separation for combined cocoa procyanidin fractions D and E;
- Fig. 150 shows a representative normal phase semi-preparative HPLC separation of a crude cocoa
- Fig. 16 shows typical Rancimat Oxidation curves for cocoa procyanidin extract and fractions in comparison to the synthetic antioxidants BHA and BHT (arbitrary units vs. time; dotted line and cross (+) is BHA and BHT; * is D-E; x is crude; open square is A-C; and open diamond is control);
- Fig. 17 shows a typical Agarose Gel indicating inhibition of topoisomerase II catalyzed decatenation of kinetoplast DNA by cocoa procyanidin fractions
- Lane 1 contains 0.5 ⁇ g of marker (M) monomer-length kinetoplast DNA circles
- Lanes 2 and 20 contain kinetoplast DNA that was incubated with Topoisomerase II in the presence of 4% DMSO, but in the absence of any cocoa procyanidins.
- Lanes 3 and 4 contain kinetoplast DNA that was incubated with Topoisomerase II in the presence of 0.5 and 5.0 ⁇ g/mL cocoa procyanidin fraction A; Lanes 5 and 6 contain kinetoplast DNA that was incubated with Topoisomerase II in the presence of 0.5 and 5.0 ⁇ g/mL cocoa procyanidin fraction B; Lanes 7, 8, 9, 13, 14 and 15 are replicates of kinetoplast DNA that was incubated with Topoisomerase II in the presence of 0.05, 0.5 and 5.0 ⁇ g/mL cocoa procyanidin fraction D; Lanes 10, 11, 12, 16, 17 and 18 are replicates of kinetoplast DNA that was incubated with Topoisomerase II in the presence of 0.05, 0.5, and 5.0 ⁇ g/mL cocoa procyanidin fraction E; Lane 19 is a replicate of kinetoplast DNA that was incubated with Topoisomerase II in the presence of 5.0 ⁇ g/mL cocoa procyanidin fraction A;
- Fig. 18 shows dose response relationships of cocoa procyanidin fraction D against DNA repair competent and deficient cell lines (fractional survival vs. ⁇ g/mL; left side xrs-6 DNA Deficient Repair Cell Line, MM-1 D D282X1; right side BR1 Competent DNA Repair Cell Line, MM-1 D D282B1);
- Fig. 19 shows the dose-response curves for Adriamycin resistant MCF-7 cells in comparison to a MCF-7 pl68 parental cell line when treated with cocoa fraction D+E (% control vs. concentration, ⁇ g/mL; open circle is MCF-7 pl68; darkened circle is MCF-7 ADR);
- Figs. 20A and B show the dose-response effects on Hela and SKBR-3 cells when treated at 100 ⁇ g/mL and 25 ⁇ g/mL levels of twelve fractions prepared by Normal phase semi- preparative HPLC (bar chart, % control vs. control and fractions 1-12);
- Fig. 21 shows a normal phase HPLC separation of crude, enriched and purified pentamers from cocoa extract
- Figs. 22A, B and C show MALDI-TOF/MS of pentamer enriched procyanidins, and of Fractions A-C and of Fractions D-E, respectively;
- Fig. 23A shows an elution profile of oligomeric procyanidins purified by modified semi-preparative HPLC
- Fig. 23B shows an elution profile of a trimer procyanidin by modified semi-preparative HPLC
- Figs. 24A-D each show energy minimized structures of all (4-8) linked pentamers based on the structure of epicatechin;
- Fig. 25A shows relative fluorescence of epicatechin upon thiolysis with benzylmercapten
- Fig. 25B shows relative fluorescence of catechin upon thiolysis with benzylmercapten
- Fig. 25C shows relative fluorescence of dimers (B2 and B5) upon thiolysis with benzylmercapten
- Fig. 26A shows relative fluorescence of dimer upon thiolysis
- Fig. 26B shows relative fluorescence of B5 dimer upon thiolysis of dimer and subsequent
- FIG. 27A shows the relative tumor volume during treatment of MDA MB 231 nude mouse model treated with pentamer
- Fig. 27B shows the relative survival curve of pentamer treated MDA 231 nude mouse model
- Fig. 28 shows the elution profile from halogen- free analytical separation of acetone extract of
- Fig. 29 shows the effect of pore size of stationary phase for normal phase HPLC separation of procyanidins
- Fig. 30A shows the substrate utilization during fermentation of cocoa beans
- Fig. 30B shows the metabolite production during fermentation
- Fig. 30C shows the plate counts during fermentation of cocoa beans
- Fig. 30D shows the relative concentrations of each component in fermented solutions of cocoa beans
- Fig. 31 shows the acetylcholine-induced relaxation of NO-related phenylephrine-precontracted rat aorta
- Fig. 32 shows the blood glucose tolerance profiles from various test mixtures
- Figs. 33A-B show the effects of indomethacin on
- Figs. 34A-B show the correlation between the degree of polymerization and IC 50 vs. COX-l/COX-2 ( ⁇ M);
- Fig. 35 shows the correlation between the effects of compounds on COX-1 and COX-2 activities expressed as ⁇ M
- Figs. 36A-V show the IC 50 values ( ⁇ M) of samples containing procyanidins with COX-1/COX-2;
- Fig. 37 shows the purification scheme for the isolation of procyanidins from cocoa
- Fig. 38A to 38P shows the preferred structures of the pentamer
- Figs. 39A-AA show a library of stereoisomers of pentamers
- Figs. 40A-B show 70 minute gradients for normal phase HPLC separation of procyanidins, detected by UV and fluorescence, respectively;
- Figs. 41A-B show 30 minute gradients for normal phase HPLC separation of procyanidins, detected by UV and fluorescence, respectively;
- Fig. 42 shows a preparation normal phase HPLC separation of procyanidins
- Figs. 43A-G show CD (circular dichroism) spectra of procyanidin dimers, trimers, tetramers, pentamers, hexamers, heptamers and octamers,
- Fig. 44A shows the structure and 1 H/ 13 C NMR data for epicatechin
- Figs. 44B-F show the APT, COSY, XHCORR, 1 H and 13 C NMR spectra for epicatechin;
- Fig. 45A shows the structure and 1 H/ 13 C NMR data for catechin
- Figs. 45B-E show the 1 H, APT, XHCORR and COSY NMR spectra for catechin
- Fig. 46A shows the structure and 1 H/ 13 C NMR data for B2 dimer
- Figs. 46B-G show the 13 C, APT, 1 H, HMQC, COSY and HOHAHA NMR spectra for the B2 dimer;
- Fig. 47A shows the structure and 1 H/ 13 C NMR data for B5 dimer
- Figs. 47B-G show the 1 H, 13 C, APT, COSY, HMQC and HOHAHA NMR spectra for B5 dimer;
- Figs. 48A-D show the 1 H, COSY, HMQC and HOHAHA NMR spectra for epicatechin/ catechin trimer
- Figs. 49A-D show the 1 H, COSY, HMQC and HOHAHA NMR spectra for epicatechin trimer
- Figs. 50A and B show the effects of cocoa procyanidin fraction A and C, respectively, on blood pressure; blood pressure levels decreased by 21.43% within 1 minute after administration of fraction A, and returned to normal after 15 minutes, while blood pressure decreased by 50.5% within 1 minute after administration of fraction C, and returned to normal after 5 minutes;
- Fig. 51 shows the effect of cocoa procyanidin fractions on arterial blood pressure in anesthetized guinea pigs
- Fig. 52 shows the effect of L-NMMA on the alterations of arterial blood pressure in anesthetized guinea pigs induced by cocoa procyanidin fraction C;
- Fig. 53 shows the effect of bradykinin on NO production by HUVEC
- Fig. 54 shows the effect of cocoa procyanidin fractions on macrophage NO production by HUVEC
- Fig. 55 shows the effect of cocoa procyanidin fractions on macrophage NO production
- Fig. 56 shows the effect of cocoa procyanidin fraction on LPS induced and gamma-Interferon primed macrophages.
- Fig. 57 shows a micellar electrokinetic
- Fig. 58 A-F show MALDI-TOF mass spectra for Cu +2 -, Zn +2 -, Fe +2 -, Fe +3 -, Ca +2 -, and Mg +2 - ions,
- Fig. 59 shows a MALDI-TOF mass spectrum of cocoa procyanidin oligomers (tetramers to octadecamers);
- Fig. 60 shows the dose-response relationship of cocoa procyanidin oligomers and the feline FeA
- lymphoblastoid cell line producing leukemia virus producing leukemia virus
- Fig. 61 shows the dose-response relationship of cocoa procyanidin oligomers and the feline CRFK normal kidney cell line
- Fig. 62 shows the dose-response relationship of cocoa procyanidin oligomers and the canine MDCK normal kidney line
- Fig. 63 shows the dose-response relationship between cocoa procyanidin oligomers and the canine GH normal kidney cell line;
- Fig. 64 shows time-temperature effects on hexamer hydrolysis
- Fig. 65 shows time-temperature effects on trimer formation.
- cocoa extracts or compounds derived therefrom exhibit anti-cancer, anti-tumor or antineoplastic activity, antioxidant activity, inhibit DNA topoisomerase II enzyme and oxidative damage to DNA, and have antimicrobial, cyclo-oxygenase and/or
- lipoxygenase apoptosis
- platelet aggregation apoptosis
- platelet aggregation apoptosis
- blood or in vivo glucose a non-steroidal antiinflammatory agent.
- the extracts, compounds or combination of compounds derived therefrom are generally prepared by reducing cocoa beans to a powder, defatting the powder, and extracting and purifying the active compound (s) from the defatted powder.
- the powder can be prepared by freeze-drying the cocoa beans and pulp, depulping and dehulling the freeze-dried cocoa beans and grinding the dehulled beans.
- the extraction of active compound(s) can be by solvent extraction techniques.
- the extracts comprising the active compounds can be purified, e.g., to be substantially pure, for instance, by gel permeation chromatography or by preparative High Performance Liquid Chromatography (HPLC) techniques or by a combination of such techniques.
- Example 25 lists the heretofore never reported concentrations of the inventive compounds found in Theobroma and Herrania species and their inter- and intra-species crosses; and Example 25 also describes methods of modulating the amounts of the inventive compounds which may be obtained from cocoa by
- procyanidins is shown in Fig. 37. Steps 1 and 2 of the purification scheme are described in Examples 1 and 2; steps 3 and 4 are described in Examples 3, 13 and 23;
- step 5 is described in Examples 4 and 14; and step 6 is described in Examples 4, 14 and 16.
- step 6 is described in Examples 4, 14 and 16.
- the skilled artisan would appreciate and envision modifications in the purification scheme outlined in Figure 37 to obtain the active compounds without departing from the spirit or scope thereof and without undue experimentation.
- cocoa polyphenol such as procyanidins.
- These cocoa procyanidins have significant anti-cancer, anti-tumor or antineoplastic activity;
- antioxidant activity inhibit DNA topoisomerase II enzyme and oxidative damage to DNA; possess antimicrobial activity; have the ability to modulate cyclo-oxygenase and/or lipoxygenase, NO or NO-synthase, apoptosis, platelet aggregation and blood or in vivo glucose, and have efficacy as non-steroidal antiinflammatory agents.
- the present invention provides a compound of the formula:
- n is an integer from 2 to 18, e.g., 3 to 12, such that there is a first monomeric unit A, and a plurality of other monomeric units;
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-( ⁇ )-O-sugar, or 3- ( ⁇ )-O-sugar;
- position 4 is alpha or beta stereochemistry
- the compound can have n as 5 to 12, and certain preferred compounds have n as 5.
- the sugar can be selected from the group consisting of glucose, galactose, xylose, rhamnose, and arabinose.
- the sugar of any or all of R, X, Y and Z can optionally be substituted with a phenolic moiety via an ester bond.
- the invention can provide a compound of the formula: wher
- n is an integer from 2 to 18, e.g., 3 to 12, advantageously 5 to 12, and preferably n is 5, such that there is a first monomeric unit A,
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-( ⁇ )-O-sugar, or 3- ( ⁇ )-O-sugar;
- position 4 is alpha or beta stereochemistry
- said sugar is optionally substituted with a phenolic moiety via an ester bond.
- the present invention provides a polymeric compound of the formula A n , wherein A is a monomer having the formula:
- n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and at least one or a plurality of additional monomeric units;
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-( a)-O-sugar, or 3-
- a bond of an additional monomeric unit in position 4 has ⁇ or ⁇ stereochemistry
- the sugar is optionally substituted with a phenolic moiety at any position, for instance via an ester bond, and pharmaceutically acceptable salts or derivatives thereof (including oxidation products).
- n can be 3 to 18, 2 to 18, 3 to 12, e.g., 5 to 12; and, advantageously, n is 5.
- the sugar is selected from the group consisting of glucose, galactose, xylose, rhamnose and arabinose.
- the sugar of any or all of R, X, Y and Z can optionally be substituted at any position with a phenolic moiety via an ester bond.
- the phenolic moiety is selected from the group consisting of caffeic, cinnamic, coumaric, ferulic, gallic, hydroxybenzoic and sinapic acids.
- the present invention provides a polymeric compound of the formula A n , wherein A is a monomer having the formula:
- n is an integer from 2 to 18, e.g., 3 to 18,
- n is 5;
- R is 3-( ⁇ )-OH, 3-( ⁇ )-OH, 3-( ⁇ )-O-sugar, or 3- ( ⁇ )-O-sugar;
- a bond at position 4 has ⁇ or ⁇
- the sugar is optionally substituted with a phenolic moiety at any position, for instance, via an ester bond,
- At least one terminal monomeric unit A it will be understood that the inventive compounds have two terminal monomeric units, and that the two terminal monomeric unit A may be the same or different. Additionally, it will be understood that the inventive compounds have two terminal monomeric units, and that the two terminal monomeric unit A may be the same or different. Additionally, it will be understood
- terminal monomeric unit A includes embodiments wherein the terminal monomeric unit A is referred to as a "first monomeric unit”, with the recitation of "first monomeric unit” relating to that monomer to which other monomeric units are added, resulting in a polymeric compound of the formula A n .
- inventive compounds may be used simultaneously, e.g., administered to a subject in need of treatment in a formulation comprising one or more inventive compounds.
- cocoa extract may be substituted by compounds of the invention or
- oligomer refers to any compounds or combinations thereof of the formula presented above, wherein n is 2 through 18.
- n 2 through 18.
- oligomer 3
- trimer 3
- oligomer 4
- tetramer 4
- n 5
- oligomer 5
- similar recitations may be designated for oligomers having n up to and including 18, such that when n is 18, the oligomer is termed an
- inventive compounds or combinations thereof can be isolated, e.g., from a natural source such as any species of Theobroma , Herrania or inter- or intra-species crosses thereof; or, the inventive compounds or
- combinations thereof can be purified, e.g., compounds or combinations thereof can be substantially pure; for instance, purified to apparent homogeneity. Purity is a relative concept, and the numerous Examples demonstrate isolation of inventive compounds or combinations thereof, as well as purification thereof, such that by methods exemplified a skilled artisan can obtain a substantially pure inventive compound or combination thereof, or purify them to apparent homogeneity (e.g., purity by separate, distinct chromatographic peak).
- a substantially pure compound or combination of compounds is at least about 40% pure, e.g., at least about 50% pure, advantageously at least about 60% pure, e.g., at least about 70% pure, more advantageously at least about 75-80% pure, preferably, at least about 90% pure, more preferably greater than 90% pure, e.g., at least 90-95% pure, or even purer, such as greater than 95% pure, e.g., 95-98% pure.
- examples of the monomeric units comprising the oligomers used herein are (+)-catechin and
- (-)-epicatechin abbreviated C and EC, respectively.
- the linkages between adjacent monomers are from position 4 to position 6 or position 4 to position 8; and this linkage between position 4 of a monomer and position 6 and 8 of the adjacent monomeric units is designated herein as (4 ⁇ 6) or (4 ⁇ 8).
- the linkages are designated herein as (4 ⁇ 6) or (4 ⁇ 8).
- the linkages are designated herein as (4 ⁇ 6) or (4 ⁇ 8).
- the linkages are designated herein as (4 ⁇ 6) or (4 ⁇ 8).
- Examples of compounds eliciting the activities cited above include dimers, EC-(4 ⁇ 8)-EC and EC-(4 ⁇ 6)- EC, wherein EC-(4 ⁇ 8)-EC is preferred; trimers [EC- (4 ⁇ 8)] 2 -EC, [EC-(4 ⁇ 8)] 2 -C and [EC-(4 ⁇ 6)] 2 -EC, wherein [EC-(4 ⁇ 8)] 2 -EC is preferred; tetramers [EC-(4 ⁇ 8)] 3 -EC, [EC-(4 ⁇ 8)] 3 -C and [EC-(4 ⁇ 8)] 2 -EC-(4 ⁇ 6)-C, wherein [EC- (4 ⁇ 8)] 3 -EC is preferred; and pentamers [EC-(4 ⁇ 8)] 4 -EC, [EC-(4 ⁇ 8)] 3 -EC-(4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 3 -EC-(4 ⁇ 8)-C and [EC-(4 ⁇ 8)] 3 -EC-(4 ⁇ 6)-C, where
- dodecamers examples of which are listed below:
- a hexamer wherein one monomer (C or EC) having linkages to another monomer (4 ⁇ 8) or (4 ⁇ 6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC; followed by a (4 ⁇ 8) linkage to a pentamer compound listed above, e.g., [EC-(4 ⁇ 8)] 5 - EC, [EC-(4B ⁇ 8)] 4 -EC-(4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 4 -EC-(4 ⁇ 8)-C, and [EC-(4 ⁇ 8)] 4 -EC-(4 ⁇ 6)-C, wherein the 3-position of the hexamer terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the hexamer is [EC-(4 ⁇ 8)] 5 -EC; A heptamer, wherein any combination of two monomers (C and/or EC) having link
- a (4 ⁇ 8) linkage to a pentamer compound listed above e.g., [EC-(4 ⁇ 8)] 6 -EC, [EC-(4 ⁇ 8)] 5 -EC- (4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 5 -EC-(4 ⁇ 8)-C, and [EC-(4 ⁇ 8)] 5 -EC- (4 ⁇ 6)-C, wherein the 3-position of the heptamer terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the heptamer is [EC-(4 ⁇ 8)] 6 -EC;
- An octamer wherein any combination of three monomers (C and/or EC) having linkages to one another (4 ⁇ 8) or (4 ⁇ 6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC;
- a (4 ⁇ 8) linkage to a pentamer compound listed above e.g., [EC-(4 ⁇ 8)] 7 -EC, [EC-(4 ⁇ 8)] 6 -EC- (4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 6 -EC-(4 ⁇ 8)-C, and [EC-(4 ⁇ 8)] 6 -EC- (4 ⁇ 6)-C, wherein the 3-position of the octamer terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the octamer is [EC-(4 ⁇ 8)] 7 -EC;
- a nonamer wherein any combination of four monomers (C and/or EC) having linkages to one another (4 ⁇ 8) or (4 ⁇ 6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC;
- a decamer wherein any combination of five monomers (C and/or EC) having linkages to one another (4 ⁇ 8) or (4 ⁇ 6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC; followed by a (4 ⁇ -*8) linkage to a pentamer compound listed above, e.g., [EC-(4B ⁇ 8)] 9 -EC, [EC-(4 ⁇ 8)] 8 -EC- (4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 8 -EC-(4 ⁇ 8)-C, and [EC-(4 ⁇ 8)] 8 -EC- (4 ⁇ -+6)-C, wherein the 3-position of the decamer terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the decamer is [EC-(4 ⁇ 8)] 9 -EC;
- An undecamer wherein any combination of six monomers (C and/or EC) having linkages to one another (4 ⁇ 8) or (4 ⁇ -6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC;
- terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the undecamer is [EC-(4 ⁇ 8)] 10 -EC; and
- a dodecamer wherein any combination of seven monomers (C and/or EC) having linkages to one another (4 ⁇ 8) or (4 ⁇ 6) for EC linked to another EC or C, and (4 ⁇ 8) or (4 ⁇ 6) for C linked to another C or EC;
- a (4 ⁇ 8) linkage to a pentamer compound listed above e.g., [EC-(4 ⁇ 8)] 11 -EC, [EC-(4 ⁇ 8)] 10 -EC- (4 ⁇ 6)-EC, [EC-(4 ⁇ 8)] 10 -EC-(4 ⁇ 8)-C, and [EC-(4 ⁇ 8)] 10 - EC-(4 ⁇ 6)-C, wherein the 3-position of the dodecamer terminal monomeric unit is optionally derivatized with a gallate or a ⁇ -D-glucose; in a preferred embodiment, the dodecamer is [EC-(4 ⁇ 8)] 11 -EC.
- Examples 3A, 3B, 4, 14, 23, 24, 30 and 34 describe methods to separate the compounds of the invention.
- Examples 13, 14A-D and 16 describe methods to purify the compounds of the invention.
- Examples 5, 15, 18, 19, 20 and 29 describe methods to identify compounds of the invention.
- Figures 38A-P and 39A-AA illustrate a stereochemical library for representative pentamers of the invention.
- Example 17 describes a method to
- Example 36 provides evidence for higher oligomers in cocoa, wherein n is 13 to 18.
- cocoa polyphenols or procyanidins or their derivatives and/or their synthetic precursors which include, but are not limited to glycosides, gallates, esters, etc. and the like. That is, the inventive compounds can be prepared from isolation from cocoa or from any species within the Theobroma or
- Derivatives can also include compounds of the above formulae wherein a sugar or gallate moiety is on the terminal monomer at positions Y or Z, or a substituted sugar or gallate moiety is on the terminal monomer at Y or Z.
- Example 8 describes the use of cocoa enzymes to oxidatively modify the compounds of the invention or combinations thereof to elicit improved cytotoxicity (see Fig. 15M) against certain cancer cell lines.
- the invention includes the ability to enzymatically modify (e.g., cleavage or addition of a chemically significant moiety) the compounds of the invention, e.g., enzymatically with polyphenol oxidase, peroxidase, catalase combinations, and/or enzymes such as hydrolases, esterases, reductases, transferases, and the like and in any combination, taking into account kinetic and thermodynamic factors (see also Example 41 regarding hydrolysis).
- inventive compounds have discrete activities, and as such, the inventive compounds have broad applicability to the treatment of a variety of disease conditions, discussed hereinbelow.
- cardiovascular diseases is the principle cause of heart attack, stroke and vascular circulation problems.
- Atherosclerosis is a complex disease which involves many cell types, biochemical events and molecular factors.
- LDL Lipoprotein
- COX COX/lipoxygenase (LOX) biochemistry and Nitric Oxide (NO) biochemistry.
- LDL plasma lipoproteins
- the oxidation of LDL is a critical event in the initiation of atheroma formation and is associated with the enhanced production of superoxide anion radical (O 2 •-).
- Oxidation of LDL by O 2 •- or other reactive species e.g., •OH,
- ONOO•-, lipid peroxy radical, copper ion, and iron based proteins reduces the affinity of LDL for uptake in cells via receptor mediated endocytosis. Oxidatively modified LDLs are then rapidly taken up by macrophages which subsequently transform into cells closely resembling the "foam cells" observed in early atherosclerotic lesions.
- Oxidized lipoproteins can also promote vascular injury through the formation of lipid hydroperoxides within the LDL particle. This event initiates radical chain oxidation reactions of unsaturated LDL lipids, thus producing more oxidized LDL for macrophage incorporation.
- Atherosclerosis leading to coronary disease As discussed generally by Jean Marx at page 320 of Science, Vol. 265 (July 15, 1994), each year about 330,000 patients in the United States undergo coronary and/or peripheral angioplasty, a procedure designed to open up blood vessels, e.g., coronary arteries, clogged by dangerous atherosclerotic plaques (atherosclerosis) and thereby restore normal blood flow. For a majority of these patients, the operation works as intended. Nearly 33% of these patients (and maybe more by some accounts), however, develop restenosis, wherein the treated arteries become quickly clogged again. These patients are no better off, and sometimes worse off, than they were before angioplasty. Excessive proliferation of smooth muscle cells (SMCs) in blood vessel walls contributes to restenosis. Increased accumulation of oxidized LDL within lesion SMCs might contribute to an atherogenic- related process like restenosis. Zhou et al.,
- cyclooxygenases are central enzymes in the production of prostaglandins and other arachidonic acid metabolites (i.e.,
- COX-1 is a constitutive enzyme expressed in many tissues, including platelets
- COX-2 a second isoform of the enzyme, is inducible by various cytokines, hormones and tumor promoters.
- COX 1 produces thromboxane A2, which is involved in platelet aggregation, which in turn is involved in the progression of atherosclerosis. Its inhibition is the basis for the prophylactic effects on cardiovascular disease.
- COX-1 and COX-2 are inhibited by aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs), and the gastric side effects of NSAIDs are believed to be associated with the inhibition of COX-1.
- NSAIDs nonsteroidal antiinflammatory drugs
- COX-2 mRNA levels are markedly increased in 86% of human colorectal adenocarcinomas.
- COX-2 expressing cell lines One significant property of COX-2 expressing cell lines is the enhanced expression of genes which participate in the modulation of apoptosis, i.e., programmed cell death.
- NSAIDs Several NSAIDs have been
- Cellular lipoxygenases are also involved in the oxidative modification of LDL through the peroxidation of unsaturated lipids.
- the generation of lipid peroxy radicals contributes to the further radical chain
- inventive compounds have utility in the treatment of diseases associated with COX/LOX.
- COX was inhibited by individual inventive compounds at
- the inventive compounds are oligomers, where n is 2 to 18.
- n is 2 to 18.
- the inventive compounds are oligomers where n is 2 to 10, and more preferably, the inventive compounds are oligomers where n is 2 to 5.
- Examples of compounds eliciting the inhibitory activity with respect to COX/LOX cited above include dimers, trimers, tetramers and pentamers, discussed above.
- the inventive compounds possess
- prostaglandins the penultimate products of the COX catalyzed conversion of arachidonic acid to prostaglandin H 2 , are involved in inflammation, pain, fever, fetal development, labor and platelet aggregation. Therefore, the inventive compounds are efficacious for the same conditions as NSAIDs, e.g., against cardiovascular disease, and stroke, etc. (indeed, the inhibition of platelet COX-1, which reduces
- Inflammation is the response of living tissues to injury. It involves a complex series of enzyme activation, mediator release, extravasation of fluid, cell migration, tissue breakdown and repair.
- Inflammation is activated by phospholipase A 2 , which liberates arachidonic acid, the substrate for COX and LOX enzymes.
- COX converts arachidonic acid to the
- prostaglandin PGE 2 the major eicosanoid detected in inflammatory conditions ranging from acute edema to chronic arthritis. Its inhibition by NSAIDs is a
- Arthritis is one of the rheumatic diseases which encompass a wide range of diseases and pathological processes, most of which affect joint tissue.
- the basic structure affected by these diseases is the connective tissue which includes synovial membranes, cartilage, bone, tendons, ligaments, and interstitial tissues.
- Temporary connective tissue syndromes include sprains and strains, tendonitis, and tendon sheath abnormalities. The most serious forms of arthritis are rheumatoid arthritis, osteoarthritis, gout and systemic lupus erythematosus.
- Inflammatory bowel disease refers to idiopathic chronic inflammatory
- inventive compounds have utility in the treatment of conditions involving inflammation, pain, fever, fetal development, labor and platelet aggregation.
- the inventive compounds have utility in the treatment of conditions associated with prostaglandin PGD 2 , PGE 2 .
- Nitric oxide is known to inhibit platelet aggregation, monocyte adhesion and chemotaxis, and proliferation of vascular smooth muscle tissue which are critically involved in the process of atherogenesis.
- cardiovascular diseases including stroke, heart attack, heart failure, irregular heart beat and kidney failure.
- Hypertension is a condition where the pressure of blood within the blood vessels is higher than normal as it circulates through the body.
- the systolic pressure exceeds 150 mm Hg or the diastolic pressure exceeds 90 mm Hg for a sustained period of time, damage is done to the body.
- excessive systolic pressure can rupture blood vessels anywhere. When it occurs within the brain, a stroke results. It can also cause
- Elevated blood pressure can also force the heart muscle to enlarge as it works harder to overcome the elevated resting (diastolic) pressure when blood is expelled. This enlargement can eventually produce irregular heart beats or heart failure.
- Hypertension is called the "silent killer" because it causes no symptoms and can only be detected when blood pressure is checked.
- the regulation of blood pressure is a complex event where one mechanism involves the expression of constitutive Ca +2 /calmodulin dependent form of nitric oxide synthase (NOS), abbreviated eNOS.
- NO produced by this enzyme produces muscle relaxation in the vessel (dilation), which lowers the blood pressure.
- eNOS nitric oxide synthase
- the vascular muscles do not relax to the appropriate degree.
- the resulting vasoconstriction increases blood pressure and may be responsible for some forms of hypertension.
- vascular endothelial cells contain eNOS.
- NO synthesized by eNOS diffuses in diverse directions, and when it reaches the underlying vascular smooth muscle, NO binds to the heme group of guanylyl cyclase, causing an increase in cGMP.
- Increased cGMP causes a decrease in intracellular free Ca +2 .
- Cyclic GMP may activate a protein kinase that phosphorylates Ca +2 transporters, causing Ca +2 to be sequestered in intracellular structures in the muscle cells. Since muscle contraction requires Ca +2 , the force of the contraction is reduced as the Ca +2 concentration declines. Muscle relaxation allows the vessel to dilate, which lowers the blood pressure.
- vasoconstriction increases blood pressure and may be responsible for some forms of hypertension.
- eNOS vasoconstriction increases blood pressure and may be responsible for some forms of hypertension.
- Pharmacological agents capable of releasing NO such as nitroglycerin or isosorbide dinitrate, remain mainstays of vasorelaxant therapy.
- NO modulation by the inventive compounds brings about a collage of beneficial effects, including the modulation of hypertension, lowering NO affected hypercholesterolemia, inhibiting platelet aggregation and monocyte adhesion, all of which are involved with the progression of atherosclerosis.
- the role of NO in the immune system is different from its function in blood vessels.
- Macrophages contain a form of NOS that is inducible, rather than constitutive, referred to as iNOS. Transcription of the iNOS gene is controlled both
- cytokines a number of biological response modifiers called cytokines.
- the most important inducers are gamma-interferon, tumor necrosis factor, interleukin-1, interleukin-2 and lipopolysaccharide
- LPS LPS
- Stimulated macrophages produce enough NO to inhibit ribonuclease reductase, the enzyme that converts ribonucleotides to the deoxyribonucleotides necessary for DNA synthesis. Inhibition of DNA synthesis may be an important way in which macrophages and other tissues possessing iNOS can inhibit the growth of rapidly dividing tumor cells or infectious bacteria.
- microorganisms play a significant role in infectious processes which reflect body contact and injury, habits, profession, environment of the
- inventive compounds, combinations thereof and compositions containing the same are useful in the treatment of conditions associated with modulating NO concentrations.
- Example 9 described the
- antioxidant activity (as inhibitors of free radicals) of the inventive compounds. Given that NO is a free radical and that the inventive compounds are strong antioxidants, it was suspected that the administration of the inventive compounds to experimental in vitro and in vivo models would have caused a reduction in NO levels. Any
- Example 27 describes an erythmia (facial flush) shortly after drinking a solution containing the
- Example 31 describes the hypotensive effects elicited by the inventive compounds in an in vivo animal model, demonstrating the efficacy of the inventive compounds in the treatment of hypertension.
- the inventive compounds, combinations thereof and compositions comprising the same comprise oligomers wherein n is 2 to 18, and preferably, n is 2 to 10.
- Example 32 describes the modulation of NO production by the inventive compounds in an in vitro model.
- the inventive compounds the inventive compounds
- compositions comprising the same comprise oligomers wherein n is 2 to 18, and preferably n is 2 to 10.
- Example 35 provides evidence for the formation of Cu +2 -, Fe +2 - and Fe +3 -oligomer complexes detected by MALDI/TOF/MS. These results indicate that the inventive compounds can complex with copper and/or iron ions to minimize their effects on LDL oxidation.
- inventive compounds have useful anti-microbial activities for the treatment of infections and for the prevention of food spoilage.
- Examples 22 and 30 describe the antimicrobial activity of the inventive compounds against several representative microbiota having clinical and food significance, as outlined below.
- inventive compounds on macrophage NO production.
- results demonstrate that the inventive compounds induce monocyte/macrophage NO production, both independent and dependent of stimulation by
- LPS lipopolysaccharide
- cytokines cytokines
- oligomers where n is 2 to 18, and preferably, are oligomers where n is 2, 4, 5, 6, 8 and 10.
- antimicrobial activity with respect to NO cited above include dimers, tetramers, pentamers, hexamers, octamers and decamers, discussed above.
- Cancers are classified into three groups:
- carcinomas are a malignancy that arises in the skin, linings of various organs, glands and tissues.
- a sarcoma is a malignancy that arises in the bone, muscle or connective tissue.
- the third group comprises leukemias and lymphomas because both develop within the blood cell forming organs.
- the major types of cancer are prostate, breast, lung, colorectal, bladder, non-Hodgkin' s lymphoma, uterine, melanoma of the skin, kidney, leukemia, ovarian and pancreatic.
- cancers of the thyroid gland, lung, breast, kidney and prostate gland frequently metastasize to the bones.
- Lung cancer commonly spreads to the brain and adrenal glands and colorectal cancer often metastasizes to the liver.
- Leukemia is considered to be a generalized disease at the onset, where it is found in the bone marrow throughout the body.
- inventive compounds are useful in the treatment of a variety of cancers discussed above.
- Examples 6, 7, 8 and 15 describe the inventive compounds which elicit anti- cancer activity against human HeLa (cervical), prostate, breast, renal, T-cell leukemia and colon cancer cell lines.
- Example 12 (Fig. 20) illustrates the dose
- Example 37 shows the same cytotoxic effects of the higher oligomers (pentamer - decamer) against a feline
- lymphoblastoid cancer cell line Cytotoxicity was also observed with higher oligomers (Figs. 58 to 61) against normal canine and feline cell lines.
- Example 8 Figs. 9D-H
- the inventive compounds were shown to elicit cytotoxicity against a putative COX-2 expressing human colon cancer cell line (HCT 116).
- Example 9 describes the antioxidant activity by the inventive compounds.
- the compounds of the invention inhibit DNA strand breaks, DNA-protein cross-links and free radical oxidation of nucleotides to reduce and/or prevent the occurrence of mutations.
- Example 10 describes the inventive compounds as topoisomerase II inhibitors, which is a target for chemotherapeutic agents, such as doxorubicin.
- Example 21 describes the in vivo effects of a substantially pure pentamer which elicited anti-tumor activity against a human breast cancer cell line (MDA-MB- 231/LCC6) in a nude mouse model (average weight of a mouse is approximately 25g). Repeat in vivo experiments with the pentamer at higher dosages (5mg) have not entirely been successful, due to unexpected animal toxicity. It is currently believed that this toxicity may be related to the vasodilation effects of the inventive compounds.
- Example 33 describes the effects of the inventive compounds on macrophage NO production.
- Macrophages which produce NO can inhibit the growth of rapidly dividing tumor cells.
- the invention includes the use of the inventive compounds to induce the inhibition of cellular proliferation by apoptosis.
- the inventive compounds are oligomers, where n is 2 to 18, e.g., 3 to 18, such as 3 to 12, and preferably, n is 5 to 12, and most preferably n is 5.
- the compounds of the invention, combinations thereof and compositions containing the same are COX inhibitors which affect platelet aggregation by inhibiting thromboxane A 2 formation, thus reducing the risk for thrombosis. Further, the inhibition of COX leads to decreased platelet and inflammatory cell
- the compounds of the invention, combinations thereof and compositions containing the same are antioxidants which suppress the oxidation of LDL by reducing the levels of superoxide radical anion and lipoxygenase mediated lipid peroxy radicals.
- compounds of the invention or combinations thereof or compositions containing compounds of the invention or combinations thereof can be used for prevention and/or treatment of atherosclerosis and/or restenosis. And thus, the inventive compounds can be administered before or after angioplasty or similar procedures to prevent or treat restenosis in patients susceptible thereto.
- the administration of the inventive compound or compounds or a composition thereof, alone or with other treatment may be continued as a regimen, e.g., monthly, bi-monthly, biannually, annually, or in some other regimen, by the skilled medical practitioner for such time as is necessary, without any undue experimentation required.
- Formulations of the inventive compounds, combinations thereof and compositions comprising the same can be prepared with standard techniques well known to those skilled in the pharmaceutical, food science, medical and veterinary arts, in the form of a liquid, suspension, tablet, capsule, injectable solution or suppository, for immediate or slow-release of the active compounds.
- the carrier may also be a polymeric delayed release system.
- Synthetic polymers are particularly useful in the formulation of a composition having controlled release. An early example of this was the polymerization of methyl methacrylate into spheres having diameters less than one micron to form so-called nano particles, reported by Kreuter, J., Microcapsules and Nanoparticles in Medicine and Pharmacology, M. Donbrow (Ed). CRC Press, p. 125-148.
- poly (d,1-lactide-co-glycolide) PLGA
- biodegradable polyester that has a long history of medical use in erodible sutures, bone plates and other temporary prostheses where it has not exhibited any toxicity.
- a wide variety of pharmaceuticals have been formulated into PLGA microcapsules. A body of data has accumulated on the adaption of PLGA for controlled, for example, as reviewed by Eldridge, J.H., et al. Current Topics in Microbiology and Immunology, 1989, 146:59-66.
- the entrapment in PLGA microspheres of 1 to 10 microns in diameter can have an effect when administered orally.
- the PLGA microencapsulation process uses a phase
- the inventive compound or compounds is or are prepared as an aqueous solution and the PLGA is dissolved in a suitable organic solvents such as methylene chloride and ethyl acetate. These two immiscible solutions are co-emulsified by high- speed stirring. A non-solvent for the polymer is then added, causing precipitation of the polymer around the aqueous droplets to form embryonic microcapsules. The microcapsules are collected, and stabilized with one of an assortment of agents (polyvinyl alcohol (PVA), gelatin, alginates, methyl cellulose) and the solvent removed by either drying in vacuo or solvent extraction.
- PVA polyvinyl alcohol
- selective processing coupled with the identification of cocoa genotypes of interest could be used to prepare Standard-of-Identity (SOI) and non-SOI chocolate products as vehicles to deliver the active compounds to a patient in need of treatment for the disease conditions described above, as well as a means for the delivery of conserved levels of the inventive compounds.
- SOI Standard-of-Identity
- non-SOI chocolate products as vehicles to deliver the active compounds to a patient in need of treatment for the disease conditions described above, as well as a means for the delivery of conserved levels of the inventive compounds.
- the benefit of this process lies in the enhanced conservation of polyphenols in contrast to that found in traditional cocoa processing, such that the ratio of the initial amount of polyphenol found in the unprocessed bean to that obtainable after processing is less than or equal to 2.
- compositions of the invention include one or more of the above noted compounds in a formulation having a pharmaceutically acceptable carrier or excipient, the inventive compounds having anti-cancer, anti-tumor or antineoplastic activities, antioxidant activity, inhibit DNA topoisomeriase II enzyme, inhibit oxidative damage to DNA, induce monocyte/macrophage NO production, have antimicrobial, cyclo-oxygenase and/or lipoxygenase, NO or NO-synthase, apoptosis, platelet aggregation and blood or in vivo glucose modulating activities, and have efficacy as non-steroidal antiinflammatory agents.
- compositions comprising the inventive compounds or combinations thereof, as well as at least one additional antineoplastic, blood pressure reducing,
- hematopoiesis agents in addition to a pharmaceutically acceptable carrier or excipient.
- compositions can be administered to a subject or patient in need of such administration in dosages and by techniques well known to those skilled in the medical, nutritional or veterinary arts taking into consideration the data herein, and such factors as the age, sex, weight, genetics and condition of the
- LD 50 toxicity
- compositions can be co-administered or sequentially administered with other antineoplastic, anti-tumor or anti-cancer agents, antioxidants, DNA topoisomerase II enzyme inhibiting agents, inhibitors of oxidatively damaged DNA or cyclo-oxygenase and/or
- lipoxygenase lipoxygenase, apoptosis, platelet aggregation, blood or in vivo glucose or NO or NO-synthase modulating agents, non-steroidal antiinflammatory agents and/or with agents which reduce or alleviate ill effects of antineoplastic, anti-tumor, anti-cancer agents, antioxidants, DNA
- topoisomerase II enzyme inhibiting agents, inhibitors of oxidatively damaged DNA, cyclo-oxygenase and/or
- lipoxygenase apoptosis, platelet aggregation, blood or in vivo glucose or NO or NO-synthase modulating and/or non-steroidal antiinflammatory agents; again, taking into consideration such factors as the age, sex, weight, genetics and condition of the particular subject or patient, and, the route of administration.
- compositions of the invention for human or veterinary use include edible compositions for oral administration, such solid or liquid formulations, for instance, capsules, tablets, pills and the like, as well as chewable solid or beverage formulations, to which the present invention may be well-suited since it is from an edible source (e.g., cocoa or chocolate flavored solid or liquid compositions); liquid preparations for orifice, e.g., oral, nasal, anal, vaginal etc., administration such as suspensions, syrups or elixirs (including cocoa or chocolate flavored compositions); and, preparations for parental, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable
- the active cocoa extract may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, DMSO, ethanol, or the like.
- a suitable carrier diluent, or excipient
- the active cocoa extract of the invention can be provided in lyophilized form for reconstituting, for instance, in isotonic aqueous, saline, glucose or DMSO buffer. In certain saline solutions, some precipitation has been observed; and, this observation may be employed as a means to isolate inventive compounds, e.g., by a "salting out" procedure.
- Example 38 describes the preparation of the inventive compounds in a tablet formulation for
- Example 39 describes the preparation of the inventive compounds in capsule formulations for similar applications. Still further, Example 40
- kits wherein the active cocoa extract is provided.
- the kit can include a separate container containing a suitable carrier, diluent or excipient.
- the kit can also include an additional anti-cancer, anti-tumor or antineoplastic agent, antioxidant, DNA topoisomerase II enzyme inhibitor or an inhibitor of oxidative DNA damage or antimicrobial, or cyclo-oxygenase and/or lipoxygenase, NO or NO-synthase non-steroidal antiinflammatory, apoptosis and platelet aggregation modulating or blood or in vivo glucose modulating agent and/or an agent which reduces or
- the additional agent (s) can be provided in separate container (s) or in admixture with the active cocoa extract. Additionally, the kit can include instructions for mixing or combining ingredients and/or administration.
- a further embodiment of the invention comprehends the modulation of genes expressed as a result of intimate cellular contact by the inventive compounds or a combination of compounds.
- the present invention comprehends methods for the identification of genes induced or repressed by the inventive compounds or a combination of compounds which are associated with several diseases, including but not limited to
- transcription factors such as nuclear factor (NF)- ⁇ B.
- the target genes for NF- ⁇ B comprise a list of genes linked to coordinated inflammatory response. These include genes encoding tumor necrosis factor (TNF)- ⁇ , interleukin (IL)-I, IL-6, IL-8, inducible NOS, Major Histocompatabilty Complex (MHC) class I antigens, and others.
- genes that modulate the activity of transcription factors may in turn be induced by oxidative stress. Oxidative stress is the imbalance between radical scavenging and radical generating systems.
- gaddl53 a gene induced by growth arrest and DNA damage
- NF-IL6 upregulates the expression of several genes, including those encoding interleukins 6 and 8.
- gadd45 Another example of oxidative stress inducible genes are gadd45 which regulates the effects of the transcription factor p53 in growth arrest.
- p53 codes for the p53 protein which can halt cell division and induce abnormal cells (e.g. cancer) to undergo apoptosis.
- the invention further comprehends strategies to determine the temporal effects on gene(s) or gene product (s) expression by the inventive compounds in animal in vi tro and/or in vivo models of specific disease or disease states using gene expression assays.
- gene expression assays include, but are not limited to Differential Display, sequencing of cDNA libraries, Serial Analysis of Gene Expression (SAGE), expression monitoring by
- RT-PCR reverse transcriptase-polymerization chain reaction
- the comprehensive physiological effects of the inventive compounds or combination of compounds embodied in the invention, coupled to a genetic evaluation process permits the discovery of genes and gene products, whether known or novel, induced or repressed.
- the invention comprehends the in vi tro and in vivo induction and/or repression of cytokines (e.g. IL-1, IL-2, IL-6, IL-8, IL-12, and TNF- ⁇ ) in lymphocytes using RT-PCR.
- cytokines e.g. IL-1, IL-2, IL-6, IL-8, IL-12, and TNF- ⁇
- the invention comprehends the application of Differential Display to ascertain the induction and/or repression of select genes; for the cardiovascular area (e.g.
- the invention under stimulated and/or oxidant stimulated conditions (e.g. TNF- ⁇ or H 2 O 2 ) conditions.
- stimulated and/or oxidant stimulated conditions e.g. TNF- ⁇ or H 2 O 2 .
- Residual solvent was removed from the defatted mass by vacuum at ambient temperature.
- Procyanidins were extracted from the defatted, unfermented, freeze dried cocoa beans of Example 1 using a modification of the method described by Jalal and
- Procyanidins were extracted from 50 gram batches of the defatted cocoa mass with 2X 400 mL 70% acetone/deionized water followed by 400mL 70%
- procyanidins are extracted from defatted, unfermented, freeze dried cocoa beans of
- Example 1 with 70% aqueous acetone. Ten grams of
- defatted material was slurried with 100 mL solvent for 5- 10 min. The slurry was centrifuged for 15 min. at 4°C at 3000 xg and the supernatant passed through glass wool. The filtrate was subjected to distillation under partial vacuum and the resultant aqueous phase frozen in liquid N 2 , followed by freeze drying on a LABCONCO Freeze Dry System. The yields of crude procyanidins ranged from 15- 20%.
- Procyanidins obtained from Example 2 were partially purified by liquid chromatography on Sephadex LH-20 (28 x 2.5 cm). Separations were aided by a step gradient from deionized water into methanol. The initial gradient composition started with 15% methanol in
- Procyanidins obtained from Example 2 and/or 3A were partially purified by semi-preparative HPLC.
- a Hewlett Packard 1050 HPLC System equipped with a variable wavelength detector, Rheodyne 7010 injection valve with lmL injection loop was assembled with a Pharmacia FRAC- 100 Fraction Collector. Separations were effected on a Phenomenex Ultracarb TM 10 ⁇ ODS column (250 x 22.5mm) connected with a Phenomenex 10 ⁇ ODS Ultracarb TM
- FIG. 15N A representative Semi-preparative HPLC trace is shown in Figure 15N for the separation of procyanidins present in fraction D + E. Individual peaks or select chromatographic regions were collected on timed intervals or manually by fraction collection for further
- Injection loads ranged from 25-100mg of material.
- Procyanidin extracts obtained from Examples 2 and/or 3A were partially purified by semi-preparative HPLC.
- a Hewlett Packard 1050 HPLC system, Millipore- Waters Model 480 LC detector set at 254nm was assembled with a Pharmacia Frac-100 Fraction Collector set in peak mode. Separations were effected on a Supelco 5 ⁇ m
- Supelcosil LC-Si column 250 x 10mm
- a Supelco 5 ⁇ m Supelguard LC-Si guard column (20 x 4.6mm).
- Procyanidins were eluted by a linear gradient under the following conditions: (Time, %A, %B); (0,82,14), (30, 67.6, 28.4), (60, 46, 50), (65, 10, 86), (70, 10, 86) followed by a 10 min. re-equilibration.
- Procyanidin extracts obtained from Example 3 were filtered through a 0.45 ⁇ filter and analyzed by a Hewlett Packard 1090 ternary HPLC system equipped with a Diode Array detector and a HP model 1046A Programmable Fluorescence Detector. Separations were effected at 45°C on a Hewlett-Packard 5 ⁇ Hypersil ODS column (200 x
- Procyanidin extracts obtained from Examples 2 and/or 3 were filtered through a 0.45 ⁇ filter and
- Procyanidins were eluted by linear gradient under the following conditions: (Time, %A, %B); (0, 82, 14), (30, 67.6, 28.4), (60, 46, 50), (65, 10, 86), (70, 10, 86) followed by an 8 min. re-equilibration.
- ⁇ em 316nm.
- Procyanidins were purified by liquid chromatography on Sephadex LH-20 (28 x 2.5cm) columns followed by semi-preparative HPLC using a lO ⁇ Bondapak C18 (100 x 8mm) column or by semi-preparative HPLC using a 5 ⁇ Supelcosil LC-Si (250 x 10mm) column.
- LIMS Secondary Ion Mass Spectrometry
- FIG. 3 shows several procyanidin structures and Figures 4A-4E show the representative HPLC
- Example 6 Anti-Cancer, Anti-Tumor or Antineoplastic
- the MTT (3-[4,5-dimethyl thiazol-2yl]-2,5- diphenyltetrazolium bromide) - microtiter plate
- Example 5 Test samples, standards (cisplatin and chlorambucil) and MTT reagent were dissolved in 100% DMSO (dimethyl sulfoxide) at a 10mg/mL concentration. Serial dilutions were prepared from the stock solutions. In the case of the test samples, dilutions ranging from 0.01 through 100 ⁇ g/mL were prepared in 0.5% DMSO.
- DMSO dimethyl sulfoxide
- All human tumor cell lines were obtained from the American Type Culture Collection. Cells were grown as mono layers in alpha-MEM containing 10% fetal bovine serum, 100 units/mL penicillin, 100 ⁇ g/mL streptomycin and 240 units/mL nystatin. The cells were maintained in a humidified, 5% CO 2 atmosphere at 37°C.
- the cells are counted and adjusted to a concentration of 50 x 10 5 cells/mL (varied according to cancer cell line). 200 ⁇ L of the cell suspension was plated into wells of 4 rows of a 96-well microtiter plate. After the cells were allowed to attach for four hours, 2 ⁇ L of DMSO containing test sample solutions were added to quadruplicate wells.
- Control wells contained a final concentration of 1% DMSO.
- Sample MM1 represented a very crude isolate of cocoa procyanidins and contained appreciable quantities of caffeine and theobromine.
- Sample MM2 represented a cocoa procyanidin isolate partially purified by gel permeation chromatography. Caffeine and theobromine were absent in MM2. Both samples were screened for activity against the following cancer cell lines using the
- MM2 Little or no activity was observed with MM1 on any of the cancer cell lines investigated.
- MM2 was found to have activity against HCT-116, PC-3 and ACHN cancer cell lines.
- both MM1 and MM2 were found to interfere with MTT such that it obscured the decrease in absorbance that would have reflected a decrease in viable cell number.
- This interference also contributed to large error bars, because the chemical reaction appeared to go more quickly in the wells along the perimeter of the plate.
- Figure 5 A typical example of these effects is shown in Figure 5.
- IC 50 value 0.5 ⁇ g/mL for the effect of MM2 on the ACHN cell line was obtained in this manner.
- Figures 4A - 4E were prepared. The samples were coded MM2A through MM2E to reflect these analytical
- Figures 6A-6D show the dose-response relationship between combinations of the cocoa extracts and PC-3 cancer cells.
- cocoa extracts especially cocoa polyphenols or
- procyanidins have significant anti-tumor; anti-cancer or antineoplastic activity, especially with respect to human PC-3 (prostate), HCT-116 (colon) and ACHN (renal) cancer cell lines.
- procyanidin fractions may be responsible for the activity against the PC-3 cell line.
- Example 7 Anti-Cancer, Anti-Tumor or Antineoplastic
- Figures 7A - 7H show the typical dose response relationship between cocoa procyanidin fractions and the PC-3 cell line.
- Figures 7D and 7E demonstrate that fractions D and E were active at an IC 50 value of 75 ⁇ g/mL.
- the IC 50 values that were obtained from dose-response curves of the other procyanidin fraction combinations ranged between 60 - 80 ⁇ g/mL when fractions D or E were present.
- the individual IC 50 values are listed in Table 6.
- Figures 8A - 8H show the typical dose response relationship between cocoa procyanidin fractions and the KB Nasopharyngeal/HeLa cell line.
- Figures 8D and 8E demonstrate that fractions D and E were active at an IC 50 value of 75 ⁇ g/mL.
- Figures 8F - 8H depict representative results obtained from the fraction combination study. In this case, procyanidin fraction combination A+B had no effect, whereas fraction combinations B+E and D+E were active at an IC 50 value of 60 ⁇ g/mL.
- the IC 50 values that were obtained from other dose response curves from other fraction combinations ranged from 60 - 80 ⁇ g/mL when fractions D or E were present.
- the individual IC 50 values are listed in Table 6. These results were essentially the same as those obtained against the PC-3 cell line.
- Figure 9A - 9H show the typical dose response relationships between cocoa procyanidin fractions and the HCT-116 colon cell line.
- Figures 9D and 9E demonstrate that fraction E was active at an IC 50 value of
- procyanidin fraction combination B+D did not show appreciable activity
- fraction combinations A+E and D+E were active at IC 50 values of 500 ⁇ g/mL and 85 ⁇ g/mL, respectively.
- the IC 50 values that were obtained from dose response curves of other fraction combinations averaged about 250 ⁇ g/mL when fraction E was present.
- the extrapolated IC 50 values are listed in Table 6.
- Figure 10A - 10H show the typical dose response relationships between cocoa procyanidin fractions and the ACHN renal cell line.
- Figures 10A - 10E indicated that no individual fraction was active against this cell line.
- Figures 10F - 10H depict representative results obtained from the fraction combination study. In this case, procyanidin fraction combination B+C was inactive, whereas the fraction combination A+E resulted in an extrapolated IC 50 value of approximately 500 ⁇ g/mL. Dose response curves similar to the C+D combination were considered inactive, since their slopes were too shallow. Extrapolated IC 50 values for other fraction combinations are listed in Table 6.
- FIGS 11A - 11H show the typical dose
- procyanidin fractions may nonetheless have utility with respect to this cell line.
- Figure 12A - 12H show the typical dose response relationships between cocoa procyanidin fractions and the SK-5 melanoma cell line. No activity could be detected from any individual fraction or combination of fractions at the doses used in the assay. However, procyanidin fractions may nonetheless have utility with respect to this cell line.
- FIGS 13A - 13H show the typical dose
- IC 50 values obtained from these assays are collectively listed in Table 6 for all the cell lines except for CCRF-CEM T-cell leukemia.
- the T-cell leukemia data was intentionally omitted from the Table, since a different assay procedure was used.
- procyanidins have significant anti-tumor, anti-cancer or antineoplastic activity.
- Example 8 Anti-Cancer, Anti-Tumor or Antineoplastic Activity of Cocoa Extracts (Procyanidins) Several additional in vi tro assay procedures were used to complement and extend the results presented in Examples 6 and 7.
- All human tumor cell lines were obtained from the American Type Culture Collection. Cells were grown as monolayers in IMEM containing 10% fetal bovine serum without antibiotics. The cells were maintained in a humidified, 5% CO 2 atmosphere at 37°C.
- the cells were counted and adjusted to a concentration of 1,000-2,000 cells per 100 mL.
- Cell proliferation was determined by plating the cells (1,000-2,000 cells/well) in a 96 well microtiter plate. After addition of 100 ⁇ L cells per well, the cells were allowed to attach for 24 hours. At the end of the 24 hour period, various cocoa fractions were added at different concentrations to obtain dose response results. The cocoa fractions were dissolved in media at a 2 fold concentration and 100 ⁇ L of each solution was added in triplicate wells. On consecutive days, the plates were stained with 50 ⁇ L crystal violet (2.5g crystal violet dissolved in 125mL methanol, 375mL water), for 15 min.
- crystal violet 2.5g crystal violet dissolved in 125mL methanol, 375mL water
- the stain was removed and the plate was gently immersed into cold water to remove excess stain. The washings were repeated two more times, and the plates allowed to dry. The remaining stain was solubilized by adding 100 ⁇ L of 0.1M sodium citrate/ 50% ethanol to each well. After solubilization, the number of cells were quantitated on an ELISA plate reader at 540nm (reference filter at 410nra) . The results from the ELISA reader were graphed with absorbance on the y-axis and days growth on the x- axis.
- Method B Soft Agar Cloning Assay Cells were cloned in soft agar according to the method described by Nawata et al. (1981). Single cell suspensions were made in media containing 0.8% agar with various concentrations of cocoa fractions. The
- Method C XTT-Microculture Tetrazolium Assay
- the XTT assay procedure described by Scudiero et al. (1988) was used to screen various cocoa fractions.
- the XTT assay was essentially the same as that described using the MTT procedure (Example 6) except for the following modifications.
- XTT ((2,3-bis(2-methoxy-4- nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H- tetrazolium hydroxide) was prepared at lmg/mL medium without serum, prewarmed to 37°C.
- PMS was prepared at 5mM PBS. XTT and PMS were mixed together; lO ⁇ L of PMS per mL XTT and 50 ⁇ L PMS-XTT were added to each well.
- the plates were mixed 30 min. on a mechanical shaker and the absorbance measured at 450-600nm. The results were plotted with the absorbance on the y-axis and days growth or concentration on the x-axis.
- Example 3B against the breast cancer cell line MCF-7 pl68 to determine which assay was most sensitive. As shown in Figure 15A, both assays showed the same dose- response effects for concentrations >75 ⁇ g/mL.
- the crystal violet assay showed higher standard deviations than the XTT assay results. However, since the crystal violet assay was easier to use, all subsequent assays, unless otherwise specified, were performed by this procedure.
- Figures 15B-15E to demonstrate the effect of a crude polyphenol extract (Example 2) on the breast cancer cell line MDA MB231, prostate cancer cell line PC-3, breast cancer cell line MCF-7 pl63, and cervical cancer cell line Hela, respectively.
- a dose of 250 ⁇ g/mL completely inhibited all cancer cell growth over a period of 5-7 days.
- the Hela cell line appeared to be more sensitive to the extract, since a 100 ⁇ g/mL dose also inhibited growth.
- Cocoa fractions from Example 3B were also assayed against Hela and another breast cancer cell line SKBR-3.
- the results (Figures 15F and 15G) showed that fraction D & E has the highest activity.
- IC 50 values of about 40 ⁇ g/mL D & E were obtained from both cancer cell lines.
- cocoa fraction D & E was also tested in the soft agar cloning assay which determines the ability of a test compound (s) to inhibit anchorage independent growth. As shown in Figure 15J, a concentration of 100 ⁇ g/mL completely inhibited colony formation of Hela cells.
- cocoa genotypes possess a polyphenol fraction that elicits activity against at least one human cancer cell line that is independent of geographical origin, horticultural race, and genotype.
- PPO polyphenol oxidase
- Crude PPO was prepared by extracting finely ground, unfermented, freeze dried, defatted Brazilian cocoa beans with acetone at a ratio of lgm powder to 10mL acetone. The slurry was centrifuged at 3,000 rpm for 15 min. This was repeated three times, discarding the supernatant each time with the fourth extraction being poured through a Buchner filtering funnel. The acetone powder was allowed to air dry, followed by assay according to the procedures described by McLord and Kilara, (1983).
- Peanut Oil was pressed from unroasted peanuts after the skins were removed. Each test compound was spiked into the oil at two levels, ⁇ 100 ppm and - 20 ppm, with the actual levels given in Table 7. 50 ⁇ L of methanol solubilized antioxidant was added to each sample to aid in dispersion of the antioxidant. A control sample was prepared with 50 ⁇ L of methanol containing no antioxidant.
- the invention may be employed in place of BHT or BHA in known utilities of BHA or BHT, for instance as an antioxidant and/or food additive. And, in this regard, it is noted too that the invention is from an edible source. Given these results, the skilled artisan can also readily determine a suitable amount of the invention to employ in such "BHA or BHT" utilities, e.g. , the quantity to add to food, without undue
- DNA topoisomerase I and II are enzymes that catalyze the breaking and rejoining of DNA strands, thereby controlling the topological states of DNA (Wang, 1985).
- topoisomerase II is the primary cellular target for a number of clinically important antitumor compounds (Yamashita et al., 1990) which include intercalating agents (m-AMSA, Adriamycin® and ellipticine) as well as nonintercalating agents
- cleavable complex which upon exposure to denaturing agents results in the induction of DNA cleavage (Muller et al., 1989). It has been suggested that the cleavable complex formation by antitumor drugs produces bulky DNA adducts that can lead to cell death.
- a specific new inducer of DNA topoisomerase II cleavable complex is useful as an anti-cancer, anti-tumor or antineoplastic agent.
- the cocoa procyanidins were screened for enhanced cytotoxic activity against several DNA - damage sensitive cell lines and enzyme assay with human topoisomerase II obtained from lymphoma.
- Figure 17 shows the results of these experiments. Fully catenated kinetoplast DNA does not migrate into a 1% agarose gel. Decatenation of
- kinetoplast DNA by topoisomerase II generates bands of monomeric DNA (monomer circle, forms I and II) which do migrate into the gel. Inhibition of the enzyme by addition of cocoa procyanidins is apparent by the
- cocoa procyanidin fractions A, B, D, and E were shown to inhibit topoisomerase II at concentrations ranging from 0.5 to 5.0 ⁇ g/mL.
- Cocoa procyanidins were screened for cytotoxicity against several DNA-damage sensitive cell lines.
- One of the cell lines was the xrs-6 DNA double strand break repair mutant developed by P. Jeggo (Kemp et al., 1984).
- the DNA repair deficiency of the xrs-6 cell line renders them particularly sensitive to x- irradiation, to compounds that produce DNA double strand breaks directly, such as bleomycin, and to compounds that inhibit topoisomerase II, and thus may indirectly induce double strand breaks as suggested by Warters et al.
- the cytotoxicity toward the repair deficient line was compared to the cytotoxicity against a DNA repair proficient CHO line, BR1.
- Enhanced cytotoxicity towards the repair deficient (xrs-6) line was interpreted as evidence for DNA cleavable double strand break
- the DNA repair competent CHO line, BRl was developed by Barrows et al. (1987) and expresses 0 6 - alkylguanine - DNA - alkyltransferase in addition to normal CHO DNA repair enzymes.
- the CHO double strand break repair deficient line (xrs-6) was a generous gift from Dr. P. Jeggo and co-workers (Jeggo et al., 1989). Both of these lines were grown as monolayers in alpha-MEM containing serum and antibiotics as described in
- Example 6 Cells were maintained at 37°C in a humidified 5% CO 2 atmosphere. Before treatment with cocoa
- procyanidins cells grown as monolayers were detached with trypsin treatment. Assays were performed using the MTT assay procedure described in Example 6.
- topoisomerase II before it has interacted with the DNA to form a noncleavable complex.
- Noncleavable complex forming compounds are relatively new discoveries. Members of the
- anthracyclines, podophyllin alkaloids, anthracenediones, acridines, and ellipticines are all approved for clinical anti-cancer, anti-tumor or antineoplastic use, and they produce cleavable complexes (Liu, 1989).
- topoisomerase II inhibitors include amonafide (Hsiang et al.,
- topoisomerase II before cleavable complexes are formed, they have chemotherapy value either alone or in
- cocoa isoctyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
- procyanidins also appear to be a novel class of
- topoisomerase II inhibitors (Kashiwada et al., 1993) and may thus be less toxic to cells than other known
- the human breast cancer cell line MCF-7 (ADR) which expresses a membrane bound glycoprotein (gpl70) to confer multi-drug resistance (Leonessa et al., 1994) and its parental line MCF-7 pl68 were used to assay the effects of cocoa fraction D & E. As shown in Figure 19, the parental line was inhibited at increasing dose levels of fraction D & E, whereas the Adriamycin (ADR) resistant line was less effected at the higher doses. These results show that cocoa fraction D & E has an effect on multi-drug resistant cell lines.
- procyanidins were synthesized according to the procedures developed by Delcour et al. (1983), with modification. In addition to condensing (+)-catechin with dihydroquercetin under reducing
- (-)-epicatechin was also used to reflect the high concentrations of (-)-epicatechin that naturally occur in unfermented cocoa beans.
- the synthesis products were isolated, purified, analyzed, and identified by the procedures described in Examples 3, 4 and 5. In this manner, the biflavanoids, triflavanoids and
- tetraflavanoids are prepared and used as analytical standards and, in the manner described above with respect to cocoa extracts.
- Procyanidins obtained as in Example 2 were partially purified by liquid chromatography on Sephadex LH 20 (72.5 x 2.5cm), using 100% methanol as the eluting solvent, at a flow rate of 3.5mL/min. Fractions of the eluent were collected after the first 1.5 hours, and the fractions were concentrated by a rotary evaporator, redissolved in water and freeze dried. These fractions were referred to as pentamer enriched fractions.
- Procyanidins obtained as Example 2 were separated purified by normal phase chromatography on Supelcosil LC-Si, 100 ⁇ , 5 ⁇ m (250 x 4.6mm), at a flow rate of l.OmL/min, or, in the alternative, Lichrosphere ®
- the procyanidins were eluted with a linear gradient of 20% B into A in 20 minutes, followed by a column wash with 100% B at a flow rate of 0.3mL/min.
- Millipore - Waters model 480 LC detector set at 254nm, which was assembled with a Pharmacia Frac-100 Fraction Collector set to peak mode. Separations were effected on a Supelco 5 ⁇ m Supelcosel LC-Si, 100 ⁇ column (250 x 10mm) connected with a Supelco 5 ⁇ Supelguard LC-Si guard column (20 x 4.6mm). Procyanidins were eluted by a linear gradient under the following conditions: (Time, %A, %B); (0, 82, 14), (30, 67.6, 28.4), (60, 46, 50), (65, 10, 86), (70, 10, 86) followed by a 10 minute reequilibration. Mobile phase composition was A
- Acetic acid levels in A and B mobile phases can be increased to 2%.
- Procyanidin levels were estimated by using the response factor for (-)-epicatechin.
- Pentamer enriched procyanidin extracts obtained as in Example 13 were filtered through a 0.45 ⁇ nylon filter and analyzed by a Hewlett Packard 1090 Series II HPLC system equipped with a HP Model 1046A Programmable Fluorescence detector and Diode Array detector.
- Procyanidins were eluted by linear gradient under the following conditions: (time, %A, %B); (0, 82, 14), (30, 67.6, 28.4), (60, 46, 50), (65, 10, 86), (70, 10, 86), followed by an 8 minute re-equilibration.
- Example 13 were further purified by preparative normal phase chromatography by modifying the method of Rigaud et al., (1993) J, Chrom. 654, 255-260.
- Solvent A preparation (82% CH 2 Cl 2 , 14% methanol, 2% acetic acid, 2% water):
- Solvent B preparation (96% methanol, 2% acetic acid, 2% water):
- Example 15 Identification of Procyanidins Procyanidins obtained as in Example 14, method
- MALDI- TOF/MS Ionization-Time of Flight/Mass Spectrometry
- HP G2025A MALDI-TOF/MS system equipped with a Lecroy 9350 500 MHz Oscilloscope.
- the instrument was calibrated in accordance with the manufacturer's instructions with a low molecular weight peptide standard (HP Part No. G2051A) or peptide standard (HP Part No. G2052A) with 2,5-dihydroxybenzoic acid (DHB) (HP Part No. G2056A) as the sample matrix.
- a low molecular weight peptide standard HP Part No. G2051A
- DHB 2,5-dihydroxybenzoic acid
- sample was dissolved in 500 ⁇ L of 70/30 methanol/water, and the sample was then mixed with DHB matrix, at a ratio of 1:1, 1:10 or 1:50 (sample:matrix) and dried on a mesa under vacuum.
- the samples were analyzed in the positive ion mode with the detector voltage set at 4.75kV and the laser power set between 1.5 and 8 ⁇ J. Data was collected as the sum of a number of single shots and displayed as units of molecular weight and time of flight.
- FIG. 22A representative MALDI-TOF/MS is shown in Figure 22A.
- Figures 22 and C show MALDI-TOF/MS spectra obtained from partially purified procyanidins prepared as described in Example 3, Method A and used for in vitro assessment as described in Examples 6 and 7, and whose results are summarized in Table 6. This data illustrates that the inventive compounds described herein were predominantly found in fractions D-E, but not A-C.
- the purified D-E fraction was subjected to MALDI-TOF/MS as described above, with the exception that the fraction was initially purified by SEP-PACK ® C-18 cartridge.
- Five (5) mg of fraction D-E in 1 mL nanopure water was loaded onto a pre-equilibrated SEP-PACK ® cartridge.
- the column was washed with 5mL nanopure water to eliminate contaminants, and procyanidins were eluted with lmL 20% methanol.
- Fractions A-C were used directly, as they were isolated in Example 3, Method A, without further purification.
- Preparative Reverse Phase HPLC Procyanidins obtained from Example 14, Method A and B and D were further separated to obtain experimental quantities of like oligomers for further structural identification and elucidation (e.g., Example 15, 18, 19, and 20).
- a Hewlett Packard 1050 HPLC system equipped with a variable wavelength detector, Rheodyne 7010 injection valve with lmL injection loop was assembled with a Pharmacia FRAC-100 Fraction Collector.
- Separations were effected on a Phenomenex Ultracarb ® 10 ⁇ ODS column (250 x 22.5mm) connected with a Phenomenex 10 ⁇ ODS Ultracarb ® (60 x 10mm) guard column.
- Procyanidins obtained from Example 14, Method A and B and D were further separated to obtain experimental quantities of like oligomers for further structural identification and elucidation (e.g., Example 15, 18, 19, and 20).
- Injection volumes were 60 ⁇ L containing I2mg of enriched pentamer. Components were detected by UV at 280nm. A representative elution profile is shown in Figure 23A.
- Example 17 Molecular Modeling of Pentamers
- epicatechin are shown in Figures 24 A-D. A helical structure is suggested. In general when epicatechin is the first monomer and the bonding is 4 ⁇ 8, a beta
- Figures 39A to 39P show a library of stereoisomers up to and including the
- COSY is a 2D-Fourier transform NMR technique wherein vertical and horizontal axes provide 1 H chemical shift and ID spectra; and a point of intersection provides a correlation between protons, whereby spin-spin couplings can be determined.
- HMQC spectra enhances the sensitivity of NMR spectra of nuclei; other than protons and can reveal cross peaks from secondary and tertiary carbons to the respective protons.
- APT is a 13 C technique used in determining the number of hydrogens present at a carbon. An even number of protons at a carbon will result in a positive signal, while an odd number of protons at a carbon will result in a negative signal.
- HMQC heterogenuclear multiple quantum coherence
- COSY Homonuclear correlation spectroscopy
- APT attached proton test
- XHCORR a variation on HMQC
- Figures 44A-E represent the NMR spectra which were used to characterize the structure of the
- FIG. 44A shows the 1 H and 13 C chemical shifts, in tabular form.
- Figures 44 B-E show 1 H, APT, XHCORR and COSY spectra for epicatechin.
- Figures 45A-F represent the NMR spectra which were used to characterize the structure of the catechin monomer.
- Figure 45A shows the 1 H and 13 C chemical shifts, in tabular form.
- Figures 44 B-F show 1 H, 13 C, APT, XHCORR and COSY spectra for catechin.
- Figures 46A-G represent the spectra which were used to characterize the structure of the B2 dimer.
- Fig. 46A shows 1 H and 13 C chemical shifts, in tabular form.
- the terms T and B indicate the top half of the dimer and the bottom half of the dimer.
- Figures 46B and C show the 13 C and APT spectra, respectively, taken on a Bruker 500 MHZ NMR, at room temperature.
- Figures 46D-G show the 1 H, HMQC, COSY and
- Figures 47A-G represent the spectra which were used to characterize the structure of the B5 dimer.
- Figure 47A shows the 13 C and 1 H chemical shifts, in tabular form.
- FIGS 47B-D show the 1 H, 13 C and APT
- Figure 47E shows the COSY spectrum, taken on an AMX-360, at room temperature, using a gradient pulse.
- Figures 47F and G show the HMQC and HOHAHA, respectively, taken on an AMX-360 MHZ NMR, at room temperature.
- Figures 48A-D represent the spectra which were used to characterize the structure of the
- benzyl mercaptan (BM) was reacted with catechin, epicatechin or dimers B2 and B5.
- Dimers B2 and B5 were hydrolyzed with benzylmercaptan by dissolving dimer (B2 or B5; 1.0 mg) in 600 ⁇ l ethanol, 40 ⁇ L BM and 20 ⁇ L acetic acid. The mixture was heated at 95°C for 4 hours under nitrogen in a
- MDA-MB-231/LCC6 cell line The cell line was grown in improved minimal essential medium (IMEM)
- mice Female six to eight week old NCr nu/nu (athymic) mice were purchased through NCI and housed in an animal facility and maintained according to the regulations set forth by the United States Department of Agriculture, and the American Association for the
- mice with tumors were weighed every other day, as well as weekly to determine appropriate drug dosing.
- MDA-MD-231 prepared by tissue culture was diluted with IMEM to 3.3 x 10 6
- Tumor volume was calculated by multiplying: length x width x height x 0.5. Tumor volumes over a treatment group were averaged and Student's t test was used to calculate p values.
- Plasma samples were obtained by cardiac puncture and stored at -70°C with 15- 20 mM EDTA for the purposes of blood chemistry
- mice previously infected with 500,000 cells subcutaneously with tumor cell line MDA-MB- 231, were randomLy separated into three groups of 5 animals each and treated by intraperitoneal injection with one of: (i) placebo containing vehicle alone
- procyanidin extract as isolated in Example 14, method D in vehicle (DMSO).
- mice died within approximately
- mice of group (i) and (ii) were treated once a week, and tumor growth was monitored for each experimental and control group. After two weeks of treatment, no signs of toxicity were observed in the mice of group (ii) and, the dose administered to this group was incrementally increased by 1/2 log scale each subsequent week.
- Table represents the dosages administered during the treatment schedule for mice of group (ii):
- inventive fractions and the inventive compounds indeed have utility in antineoplastic compositions, and are not toxic in low to medium dosages, with toxicity in higher dosages able to be determined without undue experimentation.
- Method A A study was conducted to evaluate the
- cocoa extracts 10mg/100 ⁇ L decaffeinated/
- Example 14 10mg/100 ⁇ L octamer/nonamer (92% pure) as in Example 14, method D 10mg/100 ⁇ L nonamer & higher (87% pure) as in Example 14, method D
- TSB Terypticase Soy Broth
- S. newport 10 5 cfu/mL
- the inventive compounds can be used to inhibit Helicobacter pylori .
- Helicobacter pylori has been implicated in causing gastric ulcers and stomach cancer. Accordingly, the inventive compounds can be used to treat or prevent these and other maladies of bacterial origin. Suitable routes of administration, dosages, and formulations can be determined without undue experimentation considering factors well known in the art such as the malady, and the age, weight, sex, general health of the subject.
- Bacil l us sphaeri cus (ME 12) Each strain was transferred from stock culture to fresh media. The yeasts and Acetobacter were incubated 72 hours at 26°C and the bacilli and Lactobacillus were incubated 48 hours at 37°C. The slants were harvested with 5mL phosphate buffer prior to use.
- Cocoa beans were harvested from fresh pods and the pulp and testa removed. The beans were sterilized with hydrogen peroxide (35%) for 20 seconds, followed by treatment with catalase until cessation of bubbling. The beans were rinsed twice with sterile water and the process repeated. The beans were divided into glass jars and processed according to the regimens detailed in the following Table:
- the model fermentation was monitored over the duration of the study by plate counts to assess the microbial population and HPLC analysis of the
- Herrania species or their inter or intra species specific crosses thereof can be modulated, e.g., enhanced.
- Method A The purpose of this study is to establish the relationship between procyanidins (as in Example 14, method D) and NO, which is known to induce cerebral vascular dilation.
- NO which is known to induce cerebral vascular dilation.
- HUVEC from Clonetics
- procyanidin for 24 to 48 hours.
- the supematants are collected and the nitrate content determined by calorimetric assay.
- HUVEC is incubated with
- acetylcholine which is known to induce NO production, in the presence or absence of procyanidins for 24 to 48 hours.
- the supematants are collected and nitrate content is determined by calorimetric assay.
- the role of NO is ascertained by the addition of nitroarginine or (1)-N-methyl arginine, which are specific blockers of NO synthase.
- Example 14 contracted rat artery.
- Isolated rat artery is incubated in the presence or absence of procyanidins (as in Example 14, method D) and alteration of the muscular tone is assessed by visual inspection. Both contraction or relaxation of the ray artery is determined. Then, using other organs, precontraction of the isolated rat artery is induced upon addition of epinephrine. Once the contraction is stabilized, procyanidins are added and contraction or relaxation of the rat artery is
- Rats are instrumented in order to monitor systolic and diastolic blood pressure.
- the effect of each procyanidin on the alteration of blood pressure evoked by epinephrine is determined.
- the role of NO is ascertained by the
- Blood glucose levels were measured before ingestion of test beverage, and after ingestion of the test beverage at the following timed intervals: 15, 30, 45, 60, 75, 90, 120 and 180 minutes. Before the start of each glucose tolerance test, high and low glucose level controls were determined. Each glucose tolerance test was performed in duplicate. A control test solution containing 75mg cocoa polyphenols dissolved in 10 fl. oz. distilled water (no glucose) was also performed.
- inventive compounds can be used to modulate blood glucose levels when in the presence of sugars. Table 11. Glucose Tolerance Test Dates and Control
- the subject also experienced a facial flush (erythema) and lightheadedness following ingestion of the inventive compounds, indicating modulation of
- chocolates, and inventive compounds contained therein can be used as a vehicle for pharmaceutical, veterinary and food science preparations and applications.
- Figures 33 A and B show the effects of Indomethacin on COX1 and COX2 activities.
- Figures 34 A and B shows the correlation between the degree of polymerization of the procyanidin and IC 50 with COX1 and COX2;
- Figure 35 shows the correlation between IC 50 values on COX1 and COX2.
- Figures 36 A through Y show the IC 50 values of each sample (S1 - S11) with COX1 and COX2.
- inventive compounds have analgesic, anti-coagulant, and anti- inflammatory utilities.
- COX2 has been linked to colon cancer. Inhibition of COX2 activity by the inventive compounds illustrates a plausible mechanism by which the inventive compounds have antineoplastic activity against colon cancer.
- COX1 and COX2 are also implicated in the synthesis of prostaglandins.
- the results in this Example also indicate that the inventive compounds can modulate renal functions, immune responses, fever, pain, mitogenesis, apoptosis, prostaglandin synthesis,
- ulceration e.g., gastric
- reproduction e.g., ulceration (e.g., gastric)
- modulation of renal function can affect blood pressure; again implicating the inventive compounds in modulating blood pressure, vasodilation, and coronary conditions (e.g., modulation of angiotensin, bradykinin).
- Example 9 the anti-oxidant activity of inventive compounds is shown.
- Example 26 the effect on NO is demonstrated.
- Example 27 provides evidence of a facial vasodilation.
- the inventive compounds can modulate free radical mechanisms driving physiological effects.
- lipoxygenase mediated free radical type reactions biochemically directed toward leukotriene synthesis can be modulated by the inventive compounds, thus affecting subsequent physiological effects (e.g., inflammation, immune response, coronary conditions, carcinogenic mechanisms, fever, pain, ulceration).
- antineoplastic properties there may also be a
- Example 29 Circular Dichroism/Study of Procyanidins CD studies were undertaken in an effort to elucidate the structure of purified procyanidins as in Example 14, Method D. The spectra were collected at 25°C using CD spectrum software AVIV 60DS V4.1f.
- Example 30 Inhibitory Effects of Cocoa Procyanidins on Helicobacter pylori and Staphylococcus aureus
- Pentamer enriched material was prepared as described in Example 13, Method A and analyzed as described in Example 14, Method C, where 89% was pentamer, and 11% was higher oligomers (n is 6 to 12). Purified pentamer (96.3%) was prepared as described in Example 14, Method D.
- H . pylori and Staphylococcus aureus were obtained from the American Type Culture Collection (ATCC).
- ATCC American Type Culture Collection
- the vial was rehydrated with 0.5 mL Trypticase Soy broth and the suspension transferred to a slant of fresh TSA containing 5% defibrinated sheep blood.
- the slant was incubated at 37°C for 3 to 5 days under microaerophilic conditions in anaerobic jars (5 to 10% carbon dioxide; CampyPakPlus, BBL).
- CampyPakPlus CampyPakPlus
- cocoa procyanidin fractions The effect of five cocoa procyanidin fractions on guinea pig blood pressure were investigated. Briefly, guinea pigs (approximately 400g body weight; male and female) were anesthetized upon injection of 40 mg/kg sodium pentobarbital. The carotid artery was cannulated for monitoring of the arterial blood pressure. Each of the five cocoa procyanidin fractions was injected intravenously (dose range 0.1 mg/kg - 100 mg/kg) through the jugular vein. Alterations of blood pressure were recorded on a polygraph. In these experiments, the role of NO was ascertained by the administration of L-N- methylarginine (1 mg/kg) ten minutes prior to the administration of cocoa procyanidin fractions.
- Cocoa procyanidin fractions were prepared and analyzed according to the procedures described in U.S. Patent 5,554,645, hereby incorporated herein by
- Fraction B Represents a preparative HPLC fraction comprised of pentamers-decamers. HPLC analysis revealed the following
- Fraction C Represents an enriched cocoa procyanidin fraction used in the preparation of
- L-NMMA was administered at the dose of 1 mg/kg, ten minutes prior to injection of the cocoa procyanidin fractions. As shown in Figure 52, treatment of the animals with L-NMMA completely blocked the hypotension evoked by the
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08020626A EP2110134A1 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US631661 | 1990-12-20 | ||
US63166196A | 1996-04-02 | 1996-04-02 | |
PCT/US1996/004497 WO1997036597A1 (en) | 1996-04-02 | 1996-04-02 | Cocoa extract compounds and methods for making and using the same |
WOPCT/US96/04497 | 1996-04-02 | ||
PCT/US1997/005693 WO1997036497A2 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08020626A Division EP2110134A1 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1015006A2 true EP1015006A2 (en) | 2000-07-05 |
EP1015006A4 EP1015006A4 (en) | 2003-09-24 |
Family
ID=26790948
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08020626A Withdrawn EP2110134A1 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
EP97929671A Ceased EP1015006A4 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08020626A Withdrawn EP2110134A1 (en) | 1996-04-02 | 1997-04-02 | Cocoa extract compounds and methods for making and using the same |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2110134A1 (en) |
JP (2) | JP2000506901A (en) |
CN (1) | CN1159019C (en) |
AU (1) | AU742198B2 (en) |
BR (1) | BR9710955A (en) |
CA (1) | CA2250792C (en) |
HK (1) | HK1020881A1 (en) |
PL (1) | PL329325A1 (en) |
RU (1) | RU2010111103A (en) |
WO (1) | WO1997036497A2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696485B1 (en) | 1996-04-02 | 2004-02-24 | Mars, Incorporated | Procyanidin and cyclo-oxygenase modulator compositions |
US7968140B2 (en) | 1997-09-08 | 2011-06-28 | Mars, Incorporated | Chocolates and chocolate liquor having an enhanced polyphenol content |
US6312753B1 (en) | 1996-09-06 | 2001-11-06 | Mars, Incorporated | Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses |
US6207842B1 (en) * | 1997-10-09 | 2001-03-27 | Mars Incorporated | Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives |
CN100358435C (en) * | 1998-03-12 | 2008-01-02 | 马尔斯公司 | Products containing polyphenol(S) and L-arginine to stimulate nitric oxide production |
US8507018B2 (en) | 1998-03-12 | 2013-08-13 | Mars, Incorporated | Products containing polyphenol(s) and L-arginine and methods of use thereof |
AU2004200273B2 (en) * | 1998-03-12 | 2008-02-07 | Mars, Incorporated | Products Containing Polyphenol(s) and L-Arginine to stimulate nitric oxide production |
US6805883B2 (en) | 1998-03-12 | 2004-10-19 | Mars, Incorporated | Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide |
US7011856B2 (en) * | 1998-08-05 | 2006-03-14 | Amino Up Chemical Co., Ltd. | Composition for the treatment of symptoms and conditions associated with aging |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
KR100484328B1 (en) | 1999-03-17 | 2005-04-20 | 모리나가 세이카 가부시키가이샤 | Foods containing cocoa component |
JP3260134B2 (en) | 1999-10-08 | 2002-02-25 | 信孝 鈴木 | Drugs for dysmenorrhea and endometriosis |
AU2001261004B2 (en) * | 2000-03-22 | 2006-07-13 | Mars, Incorporated | The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy |
BR0110084A (en) * | 2000-04-14 | 2002-12-31 | Mars Inc | Compositions and methods to improve vascular health |
US6627232B1 (en) * | 2000-06-09 | 2003-09-30 | Mars Incorporated | Method for extracting cocoa procyanidins |
DE10037983B4 (en) * | 2000-08-03 | 2006-04-13 | Stefan Zikeli | Polymer composition and molded articles containing it containing alkaloid |
FR2812873B1 (en) | 2000-08-11 | 2003-08-01 | Barry Callebaut France | PROCESS FOR PRODUCING POLYPHENOLS FROM COCOA BEANS |
JP4763139B2 (en) * | 2001-02-21 | 2011-08-31 | 株式会社アミノアップ化学 | Novel polyhydric phenol polymer and its use |
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US7108868B2 (en) * | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US7514107B2 (en) | 2002-03-21 | 2009-04-07 | Mars, Incorporated | Treatment of diseases involving defective gap junctional communication |
FR2838055B1 (en) * | 2002-04-05 | 2006-06-09 | Cep | NOVEL USE OF A COCOA EXTRACT AND COSMETIC AND / OR DERMATOLOGICAL COMPOSITIONS THEREFOR |
US8945518B2 (en) | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
ES2330097T3 (en) | 2002-04-30 | 2009-12-04 | Unigen Pharmaceuticals, Inc. | FORMULATION OF A MIXTURE OF FLAVANS AND FLAVONOIDS OF FREE B RING AS A THERAPEUTIC AGENT. |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
KR20030097398A (en) * | 2002-06-21 | 2003-12-31 | 이노천 | A sauce for seasoned meat containing polyphenol |
AU2004228021B2 (en) | 2003-04-04 | 2010-09-02 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
TWI279231B (en) * | 2003-10-02 | 2007-04-21 | Asahi Breweries Ltd | Neutralization agent of vacuolization toxin |
JP2007508316A (en) * | 2003-10-10 | 2007-04-05 | マーズ インコーポレイテッド | Treatment of diseases associated with ErbB2 kinase overexpression |
US9675630B2 (en) | 2004-01-28 | 2017-06-13 | Mars, Incorporated | Compositions and methods of use of A-type procyanidins |
CN101133043B (en) * | 2005-02-25 | 2012-10-10 | 国立大学法人长崎大学 | Method of producing proanthocyanidin oligomer |
JP4681363B2 (en) * | 2005-03-04 | 2011-05-11 | 美智士 谷 | Malignant tumor therapeutic agent and food and drink containing the same |
JP4942953B2 (en) * | 2005-06-30 | 2012-05-30 | サントリーホールディングス株式会社 | Analysis method of procyanidins |
KR100761248B1 (en) | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
US8609174B2 (en) | 2006-11-17 | 2013-12-17 | Barry Callebaut Ag | Method for producing a soluble cocoa product from cocoa powder |
WO2008059064A1 (en) | 2006-11-17 | 2008-05-22 | Barry Callebaut Ag | Method for producing a soluble cocoa product from cocoa powder |
GB0724716D0 (en) | 2007-12-19 | 2008-01-30 | Barry Callebaut Ag | Process |
GB0801119D0 (en) | 2008-01-22 | 2008-02-27 | Barry Callebaut Ag | Composition |
FR2927811B1 (en) * | 2008-02-27 | 2010-09-10 | Unither Dev | PHARMACEUTICAL DYE EXTRACT FROM CRANBERRY CONCENTRATED WITH PROANTHOCYANIDINES A. |
JP5462491B2 (en) * | 2009-01-21 | 2014-04-02 | 株式会社 エフェクト | Proanthocyanidin trimer |
JP5789595B2 (en) | 2009-04-03 | 2015-10-07 | ダイアナプラントサイエンシズ エス.アー.エス. | Production and extraction of procyanidins from plant cell cultures |
JP5569716B2 (en) * | 2009-06-23 | 2014-08-13 | 独立行政法人国立循環器病研究センター | Drug for inhibiting lectin-like oxidized LDL receptor |
CN102933569A (en) * | 2009-12-17 | 2013-02-13 | 新加坡国立大学 | Method of preparing derivatives/oligomers of epicatechin and applications thereof |
EP2542097B1 (en) | 2010-03-05 | 2017-11-08 | Mars, Incorporated | Palatable beverages and compositions with cocoa extract |
KR20140031835A (en) | 2010-10-04 | 2014-03-13 | 다이아나플랜트사이언시즈, 에스.에이.에스. | Production and extraction of procyanidins from plant cells cultures |
WO2012078797A1 (en) * | 2010-12-07 | 2012-06-14 | The Hershey Company | Compounds influencing fatty acid uptake and metabolism and the production of inflammatory agents and methods of isolating them from cocoa products |
US9572852B2 (en) * | 2011-02-08 | 2017-02-21 | The Product Makers (Australia) Pty Ltd | Sugar extracts |
KR101742249B1 (en) * | 2012-02-16 | 2017-05-31 | 가부시키가이샤 가마타 | Filter containing built-in capsule, cigarette provided with filter and cigarette substitute provide with filter |
ITTV20120064A1 (en) * | 2012-04-19 | 2013-10-20 | R I Group Srl | EXTRACT FOR TREATMENT OF CEFALEE PRIMITIVE |
CN103113384B (en) * | 2013-02-27 | 2015-05-20 | 安徽农业大学 | Catechin derivative named Fuzhuansu B, and preparation method and application thereof |
WO2016046375A1 (en) * | 2014-09-25 | 2016-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders |
TW201733605A (en) * | 2016-02-29 | 2017-10-01 | 明治股份有限公司 | Cocoa-derived water extract, beverage containing the same, method for producing cocoa extract, and method for extracting polyphenols |
EP3747276A1 (en) | 2019-06-04 | 2020-12-09 | ODC Lizenz AG | Cocoa-based frozen desserts and methods of their manufacture |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1584725A (en) * | 1968-01-30 | 1970-01-02 | ||
JPS5832875A (en) * | 1981-07-30 | 1983-02-25 | Nippon Shinyaku Co Ltd | Tannin |
JPS58154571A (en) * | 1982-03-08 | 1983-09-14 | Nippon Shinyaku Co Ltd | Novel tannin |
US4698360A (en) * | 1985-04-09 | 1987-10-06 | Societe Civile D'investigations Pharmacologiques D'aquitaine | Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof |
US4704292A (en) * | 1984-12-10 | 1987-11-03 | Cacaofabriek De Zaan B.V. | Cocoa |
US4797421A (en) * | 1984-07-03 | 1989-01-10 | Kikkoman Corporation | Antioxidant comprising proanthocyanidin as principal component |
EP0301975A2 (en) * | 1987-07-30 | 1989-02-01 | Martine Andrée Bonnaure-Mallet | Monomeric and/or oligomeric procyanidines for the treatment of parodontal diseases |
US4863956A (en) * | 1985-07-19 | 1989-09-05 | Inverni Della Beffa Spa | Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use |
WO1994029404A1 (en) * | 1993-06-14 | 1994-12-22 | Berkem | Polyphenol derivative compositions and preparation thereof |
WO1996010404A1 (en) * | 1994-10-03 | 1996-04-11 | Mars, Incorporated | Antineoplastic cocoa extracts, methods for making, using |
WO1996030033A1 (en) * | 1995-03-24 | 1996-10-03 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1575004A (en) * | 1976-03-23 | 1980-09-17 | Iverni Della Beffa Spa | Pharmacologically active polyphenolic substances |
JPS6425726A (en) * | 1987-04-24 | 1989-01-27 | Yuutoku Yakuhin Kogyo Kk | Agent for eliminating active oxygen free radical |
CA2128293C (en) * | 1993-12-06 | 2002-09-03 | Masayuki Tanabe | Fruit polyphenols and medicinal compositions containing them |
-
1997
- 1997-04-02 EP EP08020626A patent/EP2110134A1/en not_active Withdrawn
- 1997-04-02 BR BR9710955-0A patent/BR9710955A/en not_active Application Discontinuation
- 1997-04-02 PL PL97329325A patent/PL329325A1/en not_active Application Discontinuation
- 1997-04-02 AU AU33674/97A patent/AU742198B2/en not_active Expired
- 1997-04-02 JP JP9535612A patent/JP2000506901A/en active Pending
- 1997-04-02 CN CNB971951810A patent/CN1159019C/en not_active Expired - Lifetime
- 1997-04-02 WO PCT/US1997/005693 patent/WO1997036497A2/en not_active Application Discontinuation
- 1997-04-02 EP EP97929671A patent/EP1015006A4/en not_active Ceased
- 1997-04-02 CA CA2250792A patent/CA2250792C/en not_active Expired - Lifetime
-
1999
- 1999-12-28 HK HK99106158A patent/HK1020881A1/en not_active IP Right Cessation
-
2010
- 2010-03-23 RU RU2010111103/15A patent/RU2010111103A/en not_active Application Discontinuation
- 2010-07-30 JP JP2010173057A patent/JP2011006427A/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1584725A (en) * | 1968-01-30 | 1970-01-02 | ||
JPS5832875A (en) * | 1981-07-30 | 1983-02-25 | Nippon Shinyaku Co Ltd | Tannin |
JPS58154571A (en) * | 1982-03-08 | 1983-09-14 | Nippon Shinyaku Co Ltd | Novel tannin |
US4797421A (en) * | 1984-07-03 | 1989-01-10 | Kikkoman Corporation | Antioxidant comprising proanthocyanidin as principal component |
US4704292A (en) * | 1984-12-10 | 1987-11-03 | Cacaofabriek De Zaan B.V. | Cocoa |
US4698360A (en) * | 1985-04-09 | 1987-10-06 | Societe Civile D'investigations Pharmacologiques D'aquitaine | Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof |
US4698360B1 (en) * | 1985-04-09 | 1997-11-04 | D Investigations Pharmacologiq | Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof |
US4863956A (en) * | 1985-07-19 | 1989-09-05 | Inverni Della Beffa Spa | Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use |
EP0301975A2 (en) * | 1987-07-30 | 1989-02-01 | Martine Andrée Bonnaure-Mallet | Monomeric and/or oligomeric procyanidines for the treatment of parodontal diseases |
WO1994029404A1 (en) * | 1993-06-14 | 1994-12-22 | Berkem | Polyphenol derivative compositions and preparation thereof |
WO1996010404A1 (en) * | 1994-10-03 | 1996-04-11 | Mars, Incorporated | Antineoplastic cocoa extracts, methods for making, using |
WO1996030033A1 (en) * | 1995-03-24 | 1996-10-03 | Jlb, Inc. | Method of treating or preventing non-viral microbial infection |
Non-Patent Citations (9)
Title |
---|
AN B-J ET AL: "STRUCTURE DETERMINATION OF GLUCOSYLTRANSFERASE INHIBITORS FROM CACAO BEAN HUSK" AGRICULTURAL CHEMISTRY AND BIOTECHNOLOGY, XX, KR, vol. 6, no. 37, 1994, pages 498-502, XP001087855 ISSN: 1229-2737 * |
CHENG, JUEI TANG ET AL: "Antihypertensive principles from the leaves of Melastoma candidum" PLANTA MED. ( 1993 ), 59(5), 405-7 , XP001088259 * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OTSUKA, HIROSHI ET AL: "Studies on antiinflammatory agents. VI. Antiinflammatory constituents of Cinnamomum sieboldii Meissn" retrieved from STN Database accession no. 96:223079 HCA XP002248248 & YAKUGAKU ZASSHI (1982), 102(2), 162-72 , * |
HONG, CHUANG-YE ET AL: "The inhibitory effect of tannins on lipid peroxidation of rat heart mitochondria" J. PHARM. PHARMACOL. ( 1995 ), 47(2), 138-42 , XP001087938 * |
KOLODZIEJ, H. ET AL: "Moderate cytotoxicity of proanthocyanidins to human tumor cell lines" PHYTOTHER. RES. ( 1995 ), VOLUME DATE 1995, 9(6), 410-15 , XP001088174 * |
PORTER L J ET AL: "CACAO PROCYANIDINS: MAJOR FLAVANOIDS AND IDENTIFICATION OF SOME MINOR METABOLITES" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 5, no. 30, 1991, pages 1657-1663, XP001084175 ISSN: 0031-9422 * |
ROHRBACH M S ET AL: "STRUCTURAL DETERMINANTS OF THE PLATELET AGONIST ACTIVITY OF COTTON BRACT CONDENSED TANNIN" ENVIRONMENTAL RESEARCH, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 52, no. 2, August 1990 (1990-08), pages 199-209, XP002166001 ISSN: 0013-9351 * |
See also references of WO9736497A2 * |
VENNAT B ET AL: "PROCYANIDINS FROM THE ROOTS OF FRAGARIA VESCA: CHARACTERIZATION AND PHARMACOLOGICAL APPROACH" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 2, no. 36, February 1988 (1988-02), pages 828-833, XP001087909 ISSN: 0009-2363 * |
Also Published As
Publication number | Publication date |
---|---|
AU742198B2 (en) | 2001-12-20 |
CA2250792C (en) | 2011-09-13 |
WO1997036497A2 (en) | 1997-10-09 |
CA2250792A1 (en) | 1997-10-09 |
JP2011006427A (en) | 2011-01-13 |
EP2110134A1 (en) | 2009-10-21 |
BR9710955A (en) | 2001-03-13 |
RU2010111103A (en) | 2011-09-27 |
CN1221344A (en) | 1999-06-30 |
CN1159019C (en) | 2004-07-28 |
PL329325A1 (en) | 1999-03-29 |
WO1997036497A3 (en) | 1997-12-24 |
EP1015006A4 (en) | 2003-09-24 |
JP2000506901A (en) | 2000-06-06 |
HK1020881A1 (en) | 2000-05-26 |
AU3367497A (en) | 1997-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6670390B1 (en) | Cocoa extract compounds and methods for making and using the same | |
CA2250792C (en) | Cocoa extract compounds and methods for making and using the same | |
US5891905A (en) | Methods of treatment using procyanidin antioxidants | |
US6469053B1 (en) | Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response | |
US6423743B1 (en) | Cocoa extract compounds and methods for making and using the same | |
WO1997036597A1 (en) | Cocoa extract compounds and methods for making and using the same | |
US6696485B1 (en) | Procyanidin and cyclo-oxygenase modulator compositions | |
AU2005203665B2 (en) | Cocoa extract compounds and methods for making and using the same | |
AU783239B2 (en) | Cocoa extract compounds and methods for making and using the same | |
KR100773647B1 (en) | Cocoa extract compounds and methods for making and using the same | |
RU2394562C2 (en) | Cocoa extract compound and methods of its obtaining and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981028 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 35/78 A, 7A 61K 31/35 B, 7A 61K 31/705 B |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 35/78 A, 7A 61K 31/35 B, 7A 61K 31/705 B, 7A 61P 9/00 B, 7A 61P 29/00 B, 7A 61P 31/04 B, 7A 61P 35/00 B |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 35/00 B Ipc: 7A 61P 31/04 B Ipc: 7A 61P 29/00 B Ipc: 7A 61P 9/00 B Ipc: 7A 61K 31/704 B Ipc: 7A 61K 31/353 B Ipc: 7A 61K 35/78 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20030807 |
|
17Q | First examination report despatched |
Effective date: 20031118 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20081128 |